Featuring:

- **Premium Exhibits**
  Visit industry-sponsored exhibits to gather information and learn about new products.

- **Exhibitor Showcase Presentations**
  Non-CE presentations on new products and programs - Cypress 1C.

- **Reimbursement Resource Room**
  Learn about reimbursement help and services available.

- **Patient Advocacy Pavilion**
  Visit a variety of patient advocacy kiosks representing a range of disease types and patient support services.

- **Health Information Technology Section**
  Visit and learn how HIT tools use NCCN Content to assist oncology practices.

- **Network and Recharge**
  Connect with peers during scheduled breaks and meals.

- **NCCN Booth #560 and NCCN Foundation® Booth #440**
  - Visit and learn about resources for clinicians and patients. Staff will be available to answer questions.
  - Travel through the Exhibit Hall, visit at least six booths, and return a completed Exhibitor Passport form to receive a free prize while supplies last.
  - Drop off completed Poster Session Form(s) to enter to win Apple Airpods (3rd Generation).

Access Exhibit Hall Floor Plan

[NCCN.org/conference | #NCCN2023](NCCN.org/conference | #NCCN2023)
BE VIGILANT FOR THE HIGH-RISK FACTORS THAT CAN PUT YOUR PATIENTS IN DANGER

Identify your patients’ risk for tumor lysis syndrome (TLS) before starting anticancer therapy and take action early.

Risk stratify your patients at TLSrisk.com

© 2023 sanofi-aventis U.S. LLC. All rights reserved. Sanofi is a registered trademark of Sanofi or an affiliate.
MAT-US-2300824-v1.0-02/2023
Conference Sponsors

**Platinum**
- Eisai
- GSK
- Incyte Corporation

**Gold**
- Janssen Oncology
- Pharmacyclics LLC., an AbbVie Company
- Regeneron

**Silver**
- AstraZeneca

**Bronze**
- BeiGene
- Jazz Pharmaceuticals
- Servier Pharmaceuticals
Ahead Together

Our expertise in oncology allows us to bring groundbreaking cancer therapies to the patients who need it most.
Together with GSK Oncology offers a variety of access and reimbursement services in one location for all GSK oncology products.

Reimbursement support

- Insurance benefits investigation
- Information about prior authorizations
- Guidance on insurance denials or coverage requirements
- Coding and claims assistance for products and related services

Together with GSK Oncology does not guarantee coverage or payer reimbursement for product treatment or administration. Healthcare professionals should confirm information directly with payers.

Access assistance

- Co-pay assistance for eligible commercially insured patients
- Patient assistance program that makes free product available to eligible patients
- Information about alternative funding sources

For program terms and eligibility and to obtain a Together with GSK Oncology Enrollment Form, visit TogetherwithGSKOncology.com or call 1-844-4GSK-ONC (1-844-447-5662), Monday-Friday, (8AM TO 8PM ET).

Connect with Together with GSK Oncology today

Trademarks are owned by or licensed to the GSK group of companies.

©2022 GSK or licensor.
TWGADR1080 September 2022
Produced in USA.
Exhibitor Showcase Presentations

These non-CE presentations can be viewed on the Virtual Event Platform. Attendees can also view in-person in Cypress 1C. No pre-registration is required.

Friday, March 31
7:50 - 8:20 AM
An Overview of Clinical Data for ENHERTU (fam-trastuzumab deruxtecan-nxki) in HER2-Expressing Metastatic Breast Cancer
Presented by Daiichi Sankyo and AstraZeneca

12:05 - 12:35 PM
The POSEIDON Regimen: IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) and Platinum-Based Chemotherapy
Presented by AstraZeneca

12:40 - 1:10 PM
Multi-Cancer Early Detection through Multi-Biomarker Liquid Biopsy Testing
Presented by Exact Sciences Corporation

Saturday, April 1
7:50 - 8:20 AM
Expanded Horizons: A Post-endocrine Option for Patients with HR+/HER2- mBC
Presented by Gilead Oncology

12:05 - 12:35 PM
Herpes Zoster in Immunocompromised Populations
Presented by GSK

12:40 - 1:10 PM
Learn about a treatment option for Advanced NSCLC and two types of Advanced Skin Cancers
Presented by Regeneron

Patient Advocacy Pavilion Sponsors

Ruby
Pharmacyclics

Emerald
AstraZeneca
Beigene
Coherus
Eisai
Incyte
Invitae
Janssen Oncology

Topaz
AbbVie
AmerisourceBergen
GSK
Heron Therapeutics, Inc.

Jade
Lantheus
Servier
Stay up to date with INLYTA® (axitinib) + pembrolizumab data

To learn more, visit our booth

Scan to visit the Virtual Booth

Scan to see the full Prescribing Information
Astellas Oncology is committed to elevating the standard of cancer care. We focus on developing innovative, targeted therapies for hard-to-treat cancers with limited treatment options, which is where we see the greatest opportunity to help people living with cancer.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit www.astrazeneca-us.com and follow the Company on Twitter @AstraZenecaUS.

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. We currently market an internally discovered product in the United States, BRUKINSA® (zanubrutinib).

Cipla has been dedicated to providing access to medicines at an affordable price for 30+ years in the US. Cipla has made it a mission to provide affordable pharmaceuticals while continuing to introduce new products and innovations for the pharmaceutical industry. Cipla has supplied first to market 505b2 products like Lanreotide Injection 120mg (2022) and Leuprolide 22.5mg (2023) to the marketplace in line with its mission of Caring for Life. Cipla is ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Emerging Markets Index.

With more than 120 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.

At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit www.eisai.com/US.

Children undergoing chemotherapy are going through an extraordinarily challenging time, and the loss of hearing only compounds the difficulty. Fennec Pharma is committed to helping children at risk of hearing loss due to ototoxicity. Young children are especially vulnerable to the ototoxic effects of cisplatin-based chemotherapy because their ears are still developing. The impact of ototoxicity may be permanent, severe, and profound—with the potential to significantly impair cognitive performance and the development of social and language skills. We are committed to sparing children further hardship and helping to protect their ears against the profound threat of cisplatin-induced ototoxicity.

FLASCO is a member supported state society that focuses on providing education, timely dissemination of pertinent information and general support of the Florida professionals who have chosen the challenging medical discipline of oncology. www.flasco.org

G1 is committed to improving the lives of those impacted by cancer. Led by a team with a deep understanding of the biology of cancer and extensive development and commercialization expertise, G1 is advancing its mission to improve the lives of those affected by cancer, including by commercializing the Company’s first product.
### About Our Exhibitors

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gilead Oncology – Medical Affairs</td>
<td>#403</td>
</tr>
<tr>
<td>Gilead Oncology</td>
<td>#702</td>
</tr>
<tr>
<td>Gilead Oncology</td>
<td></td>
</tr>
<tr>
<td>Gilead is creating the future of oncology to help bring more life to people with cancer. We are focused on delivering transformational science, maximizing speed to the patient, and being a partner of choice.</td>
<td></td>
</tr>
<tr>
<td><strong>Platinum Sponsor</strong></td>
<td></td>
</tr>
<tr>
<td>GSK</td>
<td>#101</td>
</tr>
<tr>
<td>GSK Oncology is driven by our scientific heritage, deep understanding of oncology, and determination to advance the standard of care for people with cancer. Purpose-built with a focus on acute and pressing needs in rare and women's cancers, we unite science, technology and talent to get ahead of disease together.</td>
<td></td>
</tr>
<tr>
<td><strong>Platinum Sponsor</strong></td>
<td></td>
</tr>
<tr>
<td>Incyte Corporation</td>
<td>#301</td>
</tr>
<tr>
<td>Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders. The Company is advancing a diversified portfolio of clinical candidates across Oncology and Inflammation &amp; Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For more information, visit Incyte.com and follow @Incyte. Gold Sponsor</td>
<td></td>
</tr>
<tr>
<td>Janssen Biotech, Inc.</td>
<td>#501</td>
</tr>
<tr>
<td>At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson &amp; Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart.</td>
<td></td>
</tr>
<tr>
<td><strong>JNCCN—Journal of the National Comprehensive Cancer Network</strong></td>
<td>#240</td>
</tr>
<tr>
<td>JNCCN—Journal of the National Comprehensive Cancer Network is a peer-reviewed, indexed medical journal providing the latest information about best clinical practices, health services research, and translational medicine. JNCCN features updates on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), (solicited) review articles elaborating on guideline recommendations, health services research, and case reports highlighting molecular insights in patient care. JNCCN's vision is to further the mission of NCCN by serving as the primary resource for information on NCCN Guidelines; innovation in translational medicine; and scientific studies related to oncology health services research. Learn more at JNCCN.org and JNCCN360.com.</td>
<td></td>
</tr>
<tr>
<td>Karyopharm Therapeutics, Inc.</td>
<td>#220</td>
</tr>
<tr>
<td>Karyopharm Therapeutics Inc., is a commercial-stage pharmaceutical company pioneering novel cancer therapies dedicated to the discovery, development, and commercialization of novel first-in-class drugs for the treatment of cancer and other diseases. Karyopharm’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with certain blood cancers.</td>
<td></td>
</tr>
<tr>
<td>Kite Pharma</td>
<td>#803</td>
</tr>
<tr>
<td>Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer.</td>
<td></td>
</tr>
<tr>
<td>LeanTaaS</td>
<td>#622</td>
</tr>
<tr>
<td>LeanTaaS is the leading provider of AI-powered and SaaS-based capacity management and patient flow software for health systems. Our iQueue products for operating rooms, infusion centers, and inpatient beds use Lean principles and AI/ML predictive and prescriptive analytics to forecast future demand based on historical data, recent pattern shifts, and real-time insights. They help staff and providers act quickly, confidently, and decisively in response to avoid operational bottlenecks before they happen. The result? Expensive assets are utilized better, hospital ROI improves, patient access increases, and clinicians work at the top of their license with reduced administrative burden.</td>
<td></td>
</tr>
<tr>
<td>Lilly</td>
<td>#203</td>
</tr>
<tr>
<td>Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. To learn more, visit <a href="http://www.lilly.com">www.lilly.com</a>.</td>
<td></td>
</tr>
<tr>
<td>Menarini-Stemline - Commercial</td>
<td>#232</td>
</tr>
<tr>
<td>Menarini-Stemline - Medical</td>
<td>#132</td>
</tr>
<tr>
<td>Menarini-Stemline is committed to making a difference in cancer patients' lives. We invest in developing precision medicine through our pipeline of investigational drugs. Partnering with cancer experts and research institutions globally, we aim to improve our understanding of cancer to enable personalized care from early detection to precision medicine.</td>
<td></td>
</tr>
</tbody>
</table>
About Our Exhibitors

Merck & Co., Inc.  Booth #120
At Merck, our goal is to translate breakthrough science into innovative oncology medicines. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry.

Merus  Booth #720
At Merus, we are clinically advancing leading-edge, targeted treatments to address the unmet needs of patients with various types of cancer. Utilizing our proprietary technology platforms, we are developing innovative multispecific antibody therapeutics, referred to as Multiconics®.

Novartis Pharmaceuticals Corporation  Booth #422
Novartis is reimagining medicine to improve and extend people’s lives. We deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. About 106,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world. Find out more at www.novartis.com.

Oncology Nutrition Registered Dietitians/Nutritionists  Booth #620
The Oncology Nutrition Dietetic Practice Group (ON DPG) of the Academy of Nutrition and Dietetics, is the premier organization of oncology-focused nutrition professionals. Our mission is to provide leadership and support of evidence-based practice through education and research. We are a group of over 2300 Registered Dietitian-Nutritionists who provide clinical nutrition care to patients in NCI-designated centers, University cancer centers, and community-based cancer centers.

Pfizer  Booth #320
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.

PharmaEssentia  Booth #103
PharmaEssentia Corporation, based in Taipei, Taiwan, is a rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, the company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003, the company is now expanding its global presence with operations the U.S., Japan, China and Korea. Visit our website to learn more.

Bronze Sponsor

Servier Pharmaceuticals  Booth #701
Servier Pharmaceuticals is a commercial-stage pharmaceuticals company with a passion for innovation and improving the lives of patients, their families and caregivers. In the United States, Servier Pharmaceuticals is committed to building a robust portfolio, starting with oncology, with future growth driven by innovation in other areas of unmet medical need, leveraging Servier’s global portfolio and seeking acquisitions, licensing deals and partnerships. With our commercial and scientific expertise, global reach and commitment to clinical excellence, Servier Pharmaceuticals is dedicated to bringing the promise of tomorrow to the patients that we serve.

Sun Pharma  Booth #222
Sun Pharma is the world’s fourth largest specialty generic pharmaceutical company and India’s largest pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world. Its global presence is supported by manufacturing facilities spread across six continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D.

Taiho Oncology  Booth #603
The mission of Taiho Oncology is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in orally administered anti-cancer agents and has a growing pipeline of antimetabolic and selectively targeted anti-cancer agents. A subsidiary of Taiho Pharmaceutical Co., Ltd., Taiho markets its medicines for a range of tumor types in the U.S. and over sees its parent company’s European and Canadian operations in Zug, Switzerland and Oakville, Ontario, Canada.

The Oncology Nursing Society (The ONS)  Booth #521
The Oncology Nursing Society (ONS) leads the development of evidence-based oncology nursing education, tools, and resources to advance cancer care. ONS’s products support the onboarding of nurses new to oncology and offer professional development education to nurses at all levels. For more information on how your organization can incorporate ONS products into your practice, email ONS at institutions@ons.org.
Mayo Clinic Comprehensive Cancer Center Booth #431

Mayo Clinic researchers are dedicated to discovering, translating and applying scientific advances around the world. The Mayo Clinic Comprehensive Cancer Center brings physicians, researchers and scientists together to carry out team-based, patient-centered research to address unmet patient needs.

The Mayo Clinic Office of Postdoctoral Affairs and Research Training (OPART) provides support and advocacy for the professional and academic needs of Mayo Clinic research students and fellows. Its goal is to develop future leaders in biomedical research and education by focusing on the recruitment and retention of research students and fellows as well as their career development while at Mayo Clinic.

Moffitt Cancer Center Booth #331

Moffitt Cancer Center is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education.

Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,800 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.

Roswell Park Comprehensive Cancer Center Booth #432

Founded in 1898 and operating from a 29-acre campus on the Buffalo Niagara Medical Campus near downtown Buffalo, New York, Roswell Park today remains the only comprehensive cancer center designated by the National Cancer Institute (NCI) in Upstate NY, and one of only four NCI-designated comprehensive cancer centers in all of NY. In the past year, Roswell Park teams cared for more than 46,000 patients. Roswell Park helps set international standards in cancer care through its role as a founding member of the National Comprehensive Cancer Network, and consistently earns patient-satisfaction scores that are among the highest in the country.

WE’RE HERE TO HELP YOUR PATIENTS.

A blood cancer diagnosis can be overwhelming for your patients. Blood cancer patients, including those with leukemia, lymphoma, myeloma, myelodysplastic syndromes and myeloproliferative neoplasms can find hope, education, guidance and support from The Leukemia & Lymphoma Society (LLS).

Our Information Specialists complement the care you provide with FREE, in-depth personalized services that connect patients to financial assistance, patient education (including booklets, podcasts and webinars), online and in-person support, nutrition consultations and the LLS Clinical Trial Support Center for assistance with clinical trials. Please contact us at 800.955.4572 or go to www.LLS.org/resources-healthcare-professionals.
Ahead Together

Our expertise in oncology allows us to bring groundbreaking cancer therapies to the patients who need it most.

GSK
Azra AI Booth #732
Azra AI is a healthtech firm that leverages advanced AI and machine learning to automate oncology workflows. Its proven SaaS clinical intelligence solution is used by more than 200 hospitals and cancer centers across the country to identify positive cancer diagnoses and incidental findings in real-time, classify by primary site, and route those patients to cancer navigators and other staff to immediately start the cancer care journey. The results include faster time to treatment, increased navigator time with patients, and better oncology patient retention. Additionally, the solution delivers dramatic operational and financial gains through intelligent automation. Learn more at www.azra-ai.com.

CureMD Oncology Booth #631
CureMD is a leading provider of innovative health information systems and services that transform the administrative and clinical operations of community oncology practices of all sizes. Our award-winning solutions simplify decision making, streamline operations, and ensure compliance with industry standards and best practices; ultimately saving time and effort to maximize value and returns.

CVS Specialty Booth #832
Personalized Specialty Pharmacy Services - Our commitment to helping patients and their physicians manage complex drug therapies by delivering individualized patient care with compassion and dedication has made us one of the leading specialty pharmacies in the country. To learn more or to enroll patients, call 1-800-238-7828.

Outcomes4me Inc. Booth #531
Outcomes4Me is an AI-driven patient empowerment platform that helps cancer patients take a proactive approach to their care, gaining access to personalized, evidence-based treatment options and information. The company is on a mission to democratize healthcare by providing real-time, evidence-based clinical information to cancer patients, ensuring they can effectively navigate through their disease and improve their outcomes. In doing so, Outcomes4Me is working to promote health equity by generating deeper insights that improve care, and accelerating research and access to innovation. Based in Boston, Massachusetts, Outcomes4Me is a woman-led company of seasoned healthcare, oncology, pharmaceutical, consumer, and technology veterans.

PatientPoint Booth #632
PatientPoint® is the patient engagement platform more providers trust. From patient acquisition to in-office and hospital engagement to remote care, our innovative, tech-enabled solutions deliver highly relevant, personalized health experiences across the entire patient journey. More than 140k healthcare providers trust PatientPoint to help them increase practice efficiencies, enhance the patient experience and improve outcomes. See how we can do the same for you. Learn more at patientpoint.com.

Pi Health USA Booth #731
Pi Health is a health technology and research company unlocking the potential of healthcare data and revolutionizing the life sciences industry.

Ronin Booth #532
At the vanguard of patient-centric care, Ronin is a cancer intelligence solution that utilizes artificial intelligence, cutting edge data science, and machine learning to empower oncologists to improve outcomes by treating each patient individually. Ronin extracts patient data through our EHR integration and symptom monitoring app and delivers an intuitive display of relevant data at the point-of-care. Relying on our deep clinical expertise, Ronin delivers a user experience that enhances clinical efficiency, reduces time spent in EHRs, connects patients to their care teams, and arms oncologists with the data they need to make the best decision for each individual.
Cancer breakthroughs take time. That’s why we work at such a furious pace.

To stop the growth of cancer, we are developing treatments that work with the body’s natural defenses. Focusing on immunotherapy gets us closer to a future where disease is a thing of the past.

© Janssen Biotech, Inc. 08/20 cp-172797v1
Association of Community Cancer Centers (ACCC)    Kiosk #A1
ACCC’s mission is to be the leading education and advocacy organization for the cancer care community. ACCC is a powerful network of more than 30,000 multidisciplinary practitioners from 2,000 hospitals and practices nationwide. Read our blog, ACCCBuzz; tune in to our CANCER BUZZ podcast; and view our CANCER BUZZ TV channel.

Bag It    Kiosk #A2
Bag It educates, supports and empowers patients, caregivers & advocates the Bag It Bag and Escape to THRIVE, a leadership conference for cancer advocates. The Bag has a binder and resources to help patients organize medical records, cope with a diagnosis and advocate for their best quality of care. It includes publications and customizable tools designed to ensure your patients have access to current, credible information and tools to help them navigate their cancer journey.

Cholangiocarcinoma Foundation    Kiosk #A3
The Cholangiocarcinoma Foundation is the leading patient-focused, global nonprofit supporting patients and caregivers, and funding critical research for this rare bile duct cancer. An estimated 10,000 Americans are diagnosed each year with the disease. To address the urgent need for more treatment options, the Foundation has formed collaborations to improve patient outcomes. The organization’s mission is to find a cure and improve the quality of life for cholangiocarcinoma patients.

Colorectal Cancer Alliance    Kiosk #A4
The Colorectal Cancer Alliance is committed to ending colorectal cancer in our lifetime through innovative programs and partnerships aimed at increasing screening rates, reducing disparities, caring for patients, and funding groundbreaking research. The Alliance’s Patient and Family Support team is committed to providing wraparound support to patients, caregivers, and their families through live navigation and our new precision care platform, BlueHQ, which empowers patients and provides critical, personalized resources in one digital place.

Crossroads4Hope: A Network of Cancer Support    Kiosk #A5
Crossroads4Hope's network embraces all people touched by cancer-the diagnosed and their loved ones-empowering individuals through access to resources, as well as programs of support, education, wellbeing, and hope. We integrate the disciplines of Social Work, Child Life, and Public Health with other allied health professionals to provide the highest level of social and emotional support, offering the widest range of assistance and resources to support our members. Taking On Your Cancer Journey. Together.

Global Colon Cancer Association    Kiosk #A12
The Global Colon Cancer Association (GCCA) fights for equal access to quality colorectal cancer screening, testing, and medical treatments because where you live should not determine whether you can prevent or survive colorectal cancer. This goal is achieved through advocacy, education, and patient-centered policy. The GCCA partners with more than 60 organizations around the world and supports the creation of advocacy groups in developing areas with no colorectal cancer organizations.

GO2 for Lung Cancer    Kiosk #A8
GO2 for Lung Cancer transforms survivorship by working across the entire continuum of care for those who are at-risk or diagnosed with lung cancer.

Support services include:
- Helpline: 1:1 support by phone, email, and website
- LungMATCH: Treatment and trial navigation
- Phone Buddy Program: Peer matching
- Lung Cancer Living Room Series: Expert speakers share about lung cancer topics
- Online community through HealthUnlocked
- Free educational publications on a wide variety of topics

Head and Neck Cancer Alliance    Kiosk #A6
For more than 25 years, the Head and Neck Cancer Alliance (HNCA) has worked to advance prevention, detection, treatment, and rehabilitation of oral, head and neck cancer through public awareness, research, advocacy, and survivorship. Programs include peer support, educational webinars, survivorship symposium, Awareness Week program and screenings, online support community, transportation support, and the Ambassador program. HNCA is led by a volunteer Board of Directors comprised of leading medical experts in the field as well as survivors.

LungCAN & LiveLung    Kiosk #A11
Lung Cancer Action Network (LungCAN), an association of US-based nonprofit organizations focused on lung cancer, collaborates with members on projects to further our mission of advancing lung cancer education, research and survivorship.

Dusty Joy Foundation (dba LiveLung), a 501(c)(3) whose mission is advancing education, early detection, optimal care, and empathy to people impacted by lung cancer and other cancers triggered by specific biomarkers, brings patients, caregivers, providers, researchers, and others together to benefit all.
NormaLeah Ovarian Cancer Institute  Kiosk #A7
NormaLeah Ovarian Cancer Initiative is a 501(c)3 organization with a mission to enrich lives through early detection education, patient support services and research funding for ovarian cancer - the silent killer of women. We educate about the symptoms/risks, provide support to families impacted by the disease and serve as a resource for medical professionals. Our sisterSTRONG program offers individualized support and referral services for survivors and connects patients with each other. Bling4Cancer Jewelry sales help fund our initiatives.

Say YES to HOPE  Kiosk #A13
Say YES to Hope provides information, support, resources, and hope to anyone affected by metastatic cancer. YES, is changing the world for those who are diagnosed with advanced cancer and is committed to assisting this underserved population of cancer patients and their caregivers. The association between access to care and support demonstrates increased survival and improved quality of life. At a time when hope has disappeared, YES offers hope and ensures that no one fights alone.

Sharsheret  Kiosk #A14
Sharsheret is a national nonprofit that supports those facing breast or ovarian cancer, or at higher diagnostic risk. Our free, confidential support includes access to social workers, a genetic counselor, and support programs, including financial subsidies, to help women navigate their cancer experiences. Sharsheret has an array of educational brochures to share with patients and offers free professional training for your team (CE may be available). Visit us at www.sharsheret.org or call (866) 474-2274.

The Leukemia & Lymphoma Society  Kiosk #A9
The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. www.lls.org/PatientSupport

The MDS Foundation, Inc.  Kiosk #A10
The MDS Foundation is a global non-profit advocacy organization that for over 25 years has supported patients and their families as well as healthcare providers in the fields of MDS and its related diseases.

• Our Vision
Every MDS patient will benefit from our initiatives and research as early as possible.

• Our Mission
MDS Foundation supports and educates patients, their communities, and healthcare providers, and contributes to innovative research in the fields of MDS and its related continuum of diseases to better diagnose, control and ultimately cure these diseases. patients and their families as well as healthcare The MDS Foundation is a global non-profit advocacy organization that for over 25 years has supported patients and their families as well as healthcare providers in the fields of MDS and its related diseases.

• Website: www.mds-foundation.org

Triage Cancer  Kiosk #A15
Triage Cancer is a national, nonprofit organization that provides free education on legal and practical issues that may impact individuals diagnosed with cancer and their caregivers, through events, materials, and resources. The Legal & Financial Navigation Program offers one-on-one help with issues such as work, health and disability insurance, finances, and estate planning. CancerFinances.org is an online toolkit to help people manage finances after a cancer diagnosis. TriageCancer.org.

Veterans Prostate Cancer Awareness  Kiosk #A16
Veterans Prostate Cancer Awareness (VPCa) is a nonprofit organization dedicated to promoting prostate awareness in the Veteran Population. The Goals and Mission of VPCa are to:

• Provide prostate cancer educational information and promote awareness among US Veteran population.

• Educate Veterans on screening, and available treatment options when faced with a prostate cancer diagnosis and empower Men to become their own Health Advocates.

• Promote new technologies for the treatment and cure of prostate cancer.
NOW APPROVED IN A 4TH INDICATION

EVEN MORE PATIENTS MAY BE RIGHT FOR BRUKINSA

REVIEW THE TRIALS SUPPORTING THE LATEST APPROVAL

BeiGene and BRUKINSA are registered trademarks owned by BeiGene, Ltd. or its affiliates. © BeiGene, Ltd. 2023 All Rights Reserved. 0522-BRU-PRC-038 1/2023
Did You Know?

**The Myelodysplastic Syndromes (MDS) Foundation, Inc.** was established by an international group of physicians and researchers to provide an ongoing exchange of information relating to MDS. Until the Foundation was set up, no formal working group had been devoted to MDS. Since its inception, we have conducted 16 international symposia in Austria, England, the United States (Chicago, Washington, DC), Spain (Barcelona, Valencia), Czech Republic, Sweden, France, Japan, Italy, Greece, Scotland, Germany, Denmark, and Canada. The 17th International Congress will be held in Marseille, France on May 3-6, 2023.

A major MDS Foundation effort is our international information network. This network provides patients with referrals to Centers of Excellence, contact names for available clinical trials, sharing of new research and treatment options between physicians, and extension of educational support to physicians, nurses, pharmacists and patients.

In response to the needs expressed by patients, families, and healthcare professionals, we have established patient advocacy groups, research funding, and professional educational initiatives. The MDS Foundation is a publicly supported organization, exempt from federal income tax under section 501(C)(3) of the IRS code.

The MDS Foundation is a publicly supported organization, exempt from federal income tax under section 501(C)(3) of the IRS code.

Learn more about

The Myelodysplastic Syndromes Foundation, Inc.

and find additional resources here:

www.mds-foundation.org
Our mission is to advance prevention, detection, treatment and rehabilitation of oral, head and neck cancer through public awareness, research, advocacy, and survivorship.

OUR PROGRAMS
- Gas cards for patients
- Educational webinars
- Survivorship Symposium
- Peer-to-Peer support
- Ambassadors
- Oral, Head and Neck Cancer Awareness

HOST A SCREENING
Sign up to host a free screening for head and neck cancer during Oral, Head and Neck Cancer Awareness Week - April 16-22

MOVE-A-THON
Join our national fundraising event in April. Move with us and raise funds to support our mission

SIGN UP FOR OUR NEWSLETTER AND STAY UP TO DATE WITH US!
HEADANDNECK.ORG
Until cancer is no longer feared, we will work tirelessly to help extend lives, ease burden, and restore hope.

We advance potentially transformative therapies to help improve the lives of people living with cancer. Our current focus centers around:

- Lung Cancer
- Multiple Myeloma and Other Blood Cancers
- Prostate Cancer

Whether it’s pursuing scientific discoveries, developing breakthrough oncology medicines, or seeking answers for patients, Sanofi never settles.
THE LATEST DATA ARE ROLLING OUT

See more at DARZALEXHCP.com

DARZALEX Faspro®
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000 units
LEARN MORE ABOUT A SUBCUTANEOUS TREATMENT OPTION

DARZALEX Faspro®
(daratumumab and hyaluronidase-fihi)
Injection for subcutaneous use | 1,800mg/30,000 units

See more at DARZALEXHCP.com
The Florida Society of Clinical Oncology (FLASCO) is a nationally recognized state professional society that serves as an essential resource for advocacy, education, communication, and research supporting those engaged in the battle against cancer.

Membership

Membership is complimentary and there are no dues for Regular, Affiliate, and Associate Members through December 31, 2023. If a member attends one FLASCO sponsored or co-sponsored event before December 31, 2023, they are eligible for another two years of free membership. Associate Members receive complimentary membership.

"The Voice of Oncology in Florida"

FLASCO Events

March 25, 2023  Fellows & Residents Training Program
April 14-15, 2023  Business of Oncology & Spring Session
Oct. 19-21, 2023  Fall Session
Nov. 3-5, 2023  Disparities & Health Equity Summit

Advocacy  Education  Communication  Research

Connect with FLASCO

www.flasco.org  Florida Society of Clinical Oncology  @FLASCO_ORC  @FloridaSocietyofClinicalOncology  @flasco_voiceofoncology
Free, personalized support for colorectal cancer.

BlueHQ is a free all-inclusive support hub for patients with colorectal cancer and their caregivers.

Sign up for access to a supportive community, vital resources, and help tracking treatments.

Visit BlueHQ.org to learn more.

Bling4Cancer is a collection of sparkling crystal beads, charms and awareness ribbons in 20 colors to correspond with all cancer and medical illness awareness colors. Choose from pre-designed items or create a custom made look! They're vibrant accessories that can fashionably honor someone who has been touched by cancer. Quantity discounts available.

Visit the NormaLeah Ovarian Cancer Initiative kiosk in the Advocacy Pavilion to learn about ovarian cancer and how we are enriching lives. Be sure to take home some FREE educational materials to share with patients.
“I looked for a cancer center with world-class facilities and resources, where they design clinical trials and prioritize immunotherapy research. I intend to make Roswell Park a world leader in innovative cellular therapy.”

– Renier Brentjens, MD, PhD
Deputy Director and Chair, Department of Medicine
Did you know...
- Veterans are 40% more likely to develop Prostate Cancer?
- If prostate cancer is detected early there is a 99.9% probability of cure?
- Prostate Cancer is detected late the probability of cure drops to 30%
- The number of prostate cancer diagnosis will surpass breast cancer in the USA in 2022
- To screen for the disease, you need an annual PSA test?

Visit Veterans Prostate Cancer Awareness to learn the facts!

Fighting Prostate Cancer with Awareness, Research & Innovation www.VPCa.vet

Crossroads4Hope™
A NETWORK OF CANCER SUPPORT

Closing the Cancer Care Gap
- MyGo2Support, 24/7 Digital Program
- Decision Support Preparation
- Resources and Referrals
- Financial Assistance
- Support4Families
- Individual and Group Support
- Social Connections
- Educational Workshops
- Nutrition Programs
- Mind Body Programs

3 Crossroads Drive, Bedminster, NJ 07921 | 908-658-5400 | crossroads4hope.org
Enrolling Investigational Trials for

Multiple Types of Hematologic Malignancies.

For more information and to see if your patients may qualify, visit

MerckClinicalTrials.com/Oncology
**Hematologic malignancies**

**MK-4280-003**
- Evaluating a combination of MK-4280, an investigational lymphocyte activation gene-3 (LAG3) inhibitor, and pembrolizumab in participants with **hematologic malignancies**

**MK-1026-003**
- Evaluating MK-1026, an investigational inhibitor of Bruton’s tyrosine kinase (BTK), in multiple relapsed/refractory hematologic malignancies including CLL/SLL, Richter’s transformation, MZL, MCL, FL, and WM

**Diffuse large B-cell lymphoma**

**MK-2140-003**
- Evaluating MK-2140, an investigational antibody-drug conjugate (ADC), in combination with chemotherapy, for relapsed/refractory DLBCL

**MK-2140-004**
- Evaluating MK-2140, an investigational antibody-drug conjugate (ADC) for patients with relapsed/refractory DLBCL who have not responded to other treatment options

**B-cell malignancies**

**MK-2140-006**
- Evaluating MK-2140, an investigational antibody-drug conjugate (ADC), for participants with aggressive and indolent B-cell malignancies including MCL, FL, Richter’s transformation, and CLL/SLL

**Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)**

**MK-1026-008**
- Evaluating MK-1026, an investigational inhibitor of Bruton’s tyrosine kinase (BTK), versus chemoimmunotherapy for previously untreated CLL/SLL without TP53 aberrations

**MK-1026-010**
- Evaluating MK-1026 (an investigational inhibitor of Bruton’s tyrosine kinase [BTK]) plus venetoclax, versus venetoclax plus rituximab, in participants with relapsed/refractory CLL/SLL following at least 1 prior therapy

**Hodgkin lymphoma**

**MK-3475-667**
- Evaluating pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma with inadequate (slow early) response to frontline chemotherapy

**MK-4280A-008**
- Evaluating MK-4280A, an investigational cof ormulation of MK-4280 (an investigational lymphocyte activation gene-3 [LAG3] inhibitor) plus pembrolizumab versus physician’s choice chemotherapy in PD-(L)1-refractory, r/r classical Hodgkin lymphoma
## General Poster Session I

**Hosted by NCCN Oncology Research Program (ORP)**

**Session I | Friday, March 31**

**Breakfast 7:30 - 8:30 AM | Morning Break 10:25 - 10:45 AM | Lunch 12:00 - 1:15 PM | Afternoon Break 3:25 - 3:45 PM**

### # | Presenting Author and Institution | Title | Co-Authors | Category
--- | --- | --- | --- | ---
1 | Qing Deng, PhD  
The University of Texas MD Anderson Cancer Center  
NCCN Member Institution | Targeting NKG2D Ligands is Therapeutically Effective in NSCLC | Min-Jae Lee, PhD; Farjana Fattah, PhD; Shoheli Koyama, MD; David Gerber, MD; Ezra Akbay, PhD | Pre-Clinical Oncology
2 | Erik S. Blomain, MD, PhD  
Stanford Cancer Institute  
NCCN Member Institution | Evolutionary Pressures Shape Soft Tissue Sarcoma Development and Response to Radiotherapy | Anish Somani; Ajay Subramanian, BS; Shaghayegh Soudi, PhD; Eniola Obidipo, BS; Christin New, BA; Deborah E. Kenney, MS; Neda Nemati-Gorgani, MS; Susan M. Hiniker, MD; Alexander L. Chin, MD, MBA; Refat S. Avedian, MD; Robert J. Steffner, MD; David G. Mohler, MD; Matt van de Rijn, MD; Everett Moding, MD, PhD | Correlative/Genomic
3 | Caitlin Zebley, MD, PhD  
St. Jude Children's Research Hospital  
NCCN Member Institution | CD19-CAR T Cells Develop Exhaustion Epigenetic Programs During a Clinical Response | Charmaine C. Brown, BS; Tian Mi, BS; Ying Fan, PhD; Shanta Alli, PhD; Shannon Boi, PhD; Giovanni Galliatti, PhD; Enrico Lugli, PhD; Deanna Langfitt, PhD; Jean-Yves Metais, PhD; Timothy Lockey, PhD; Michael Meagher, PhD; Brandon Triplett, MD; Aimee Talleur, MD; Stephen Gottschalk, MD | Clinical Oncology
4 | Deborah M. Stephens, DO  
Huntsman Cancer Institute at the University of Utah  
NCCN Member Institution | Non-melanoma Skin Cancer (NMSC) in Patients with Chronic Lymphocytic Leukemia (CLL): Biology and Prevention | Kenneth Boucher, PhD; David A. Wada, MD; Aaron Atkinson, PhD; Jack Abbott, MD; Marianne Bowling, DNP; Justin Williams, BS; Anthony D. Pomicter, MS; Renee Vadeboncoeur, MSN; APRN; Clayton Savage, APRN; Brynn Parsegov, PA-C; Lindsey Gilstrap, BS; Christa Shorter, BS; Harsh Shah, DO; Boyu Hu, MD; Lindsey Fitzgerald, MD | Clinical Oncology
5 | William Jackson, MD  
University of Michigan Rogel Cancer Center  
NCCN Member Institution | Early Interim Analysis of a Phase II Randomized Trial of Moderate Versus Ultrahypofractionated Post-Prostatectomy Radiation Therapy | Kritika Suresh, PhD; Daniel E. Spratt, MD; Robert T. Hess, MD | Clinical Oncology
6 | Ravi B. Parikh, MD, MPP  
Abramson Cancer Center at the University of Pennsylvania  
NCCN Member Institution | BE-EPIC: Behavioral Economic Interventions to Embed Palliative Care in Community Oncology | Ramy Sedhom, MD; William J. Ferrell, MPH; Katherine Villarin, BS; Karla Bervanger, BS; Bethann Scarbrough, MD; Randall Oyer, MD; Pallavi Kumar, MD, MPH; Nilanka Ganta, MD, MPH; Shanthi Sindervand, MD; Jimbo Chen, PhD; Kevin G. Volp, MD, PhD; Justin E. Bekelman, MD | Best Practices in Implementation and Use of Clinical Practice Guidelines
7 | Chien-Hsuan Huang, MD  
Taipei Medical University Hospital | Do Proton Pump Inhibitors Affect the Effectiveness of Cepacitabine-Based Chemotherapy in Colorectal Cancers? A Systematic Review with Meta-Analysis | Andrea S., MD; Yi-No Kang, MA; Yu Chang, MD; Kuan-Yu Chi, MD | Clinical Oncology
8 | Tarun Chowdary Gogineni, MCH  
GSL Medical College and General Hospital | Cervical Cancer Screening Among the Rural Indians – A Community Based Prospective Study | NA | Epidemiology/Risks/Prevention
9 | Akhil Jain, MD  
Mercy Fitzgerald Hospital | Disparities in Outcomes of Chemotherapy-Related Febrile Neutropenia Patients: A Nationwide Study of Hospitalizations | Soheli Deshpande, MD; Krishna Desai, MD; Sabah Isgal, MD; Aisha Sultan, MD; Monica Garag, MDS; Bohdan Baralo, MD; Rajesh Thirumaran, MD | Clinical Oncology
10 | Veronika Patsko, MD  
National Cancer Institute of Ukraine | Total Neoadjuvant Chemotherapy Followed by HIPEC and Curative Surgery in Treatment of Locally Advanced Gastric Cancer | Oleksii Dobrizhanskyi, MD; Yuriy Kondratskyi, MD, PhD | Clinical Oncology
11 | Anne Shah, PhD  
AstraZeneca Pharmaceuticals LP  
NCCN Member Institution | Real-World Study of Disease Free Survival & Associated Patient Characteristics in Early-stage Non-Small Cell Lung Cancer (NSCLC): A Retrospective Observational Study | Jon Appie, PharmD; Andrew J. Belli, MPH; Anna Barcellos, MPH; Eric Hansen, MS; Laura L. Fernandez, PhD; Ching-Kun Wang, MD | Outcomes and Health Services Research
12 | Anne Shah, PhD  
AstraZeneca Pharmaceuticals LP  
NCCN Member Institution | Real-World EGRF Testing in Patients with Surgically Resected Stage I-III Non-Small Cell Lung Cancer (NSCLC) in US Community Oncology Practices | Jon Appie, PharmD; Joanne Willey, RN; Michael Ayars, PhD; Daniel Simmons, PharmD; Dana Nickleach, MA; Ganiat Mumune, MM; Marnish Patel, MD; Kristen Brunskill, MS | Outcomes and Health Services Research

---

### Follow the Expert Guided Poster Tours

Open to all attendees. No pre-registration required. Experts from NCCN Member Institutions will lead a group of conference attendees and highlight research. **Meet at NCCN Booth #560 at 12:25 PM on Friday and Saturday.**
<table>
<thead>
<tr>
<th>#</th>
<th>Presenting Author and Institution</th>
<th>Title</th>
<th>Co-Authors</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>Akhil Jain, MD  Mercy Fitzgerald Hospital</td>
<td>Prevalence of Substance Use in Cancer Patients at a 5-Year Difference: A Cross-Sectional Study from Nationally Representative Population</td>
<td>Sabah Isabal, MD; Sohiei Dehshyande, MD; Krishna Desai, MD; Aisha Sultana, MD; Kristal Pereria, MD; Monika Garg, MDS; Bohdan Baralo, MD; Rajesh Thirumaran, MD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>14</td>
<td>Walid Galal Elshaddy, MD  Alexandria University Faculty of Medicine</td>
<td>Laparoscopic Complete Mesocolic Excision Versus Standard Laparoscopic Right Hemicolectomy in Egyptian Right Colon Cancer</td>
<td>Mohamed Abdelhalim, FRCS; Ahmed Mohammed Radwan, FRCS; Ann Samir, FRCS</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>15</td>
<td>Fay Fieruzech Ansary, PharmD  NC/DA, Inc.</td>
<td>Positive Quality Intervention in Action: Implementation and Value in Practice</td>
<td>Natasha Olson, PharmD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>16</td>
<td>Moni Heay, MSN  Houston Methodist Sugar Land Hospital</td>
<td>Using NCCN Distress Thermometer to Screen Cancer Patients on an Inpatient Oncology Unit</td>
<td>NA</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>17</td>
<td>Mason Alford, MSc  Vanderbilt-Ingram Cancer Center  NCCN Member Institution</td>
<td>Evaluating the Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Breast and Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Candace J. Grisham, MS; Christopher Thompson, PhD, MS; Wade T. Iams, MD, MSCI</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>18</td>
<td>Mark R. Korst, BS; Joseph G. Santitoto, BS  Rutgers New Jersey Medical School</td>
<td>Characterizing Opioid Prescribing Trends of Medical Oncologists From 2013-2019</td>
<td>Marco Santos Teles, BS; Hassaam S. Choudhry, BS; Joshua A. Kra, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>19</td>
<td>Derek Dale Ang Bayquen, BS  Cleveland Clinic Abu Dhabi</td>
<td>Patient Reported Quality of Life (QoL) Among Adults Admitted for Oncology Care in Abu Dhabi, United Arab Emirates (UAE)</td>
<td>Derek Dale Ang Bayquen, BS; Aaron Thrush, DPT</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>20</td>
<td>Abdenour Nabid, MD, FRCP  GIUSSS de l’Estrie CHUS: Centre Integre Universitaire de Sante et de Services Sociaux de l’Estrie Centre Hospitalier Universitaire de Sherbrooke du Quebec</td>
<td>Comparison of Outcomes Using NCCN Classification in Two Concurrent Phase III Trials in Intermediate and High Risk Prostate Cancer: Long-term Data</td>
<td>Nathalie Carrier, MSc; Eric Vigneault, MD; Andre-Guy Martin, MD; Thu Van Nguyen, MD; Jean-Paul Bahary, MD, FRCP(c); MSc; Peter Vavassiss, MD; Marc-Andre Brassard, MD; Sylvie Vass, MD; Boris Bahoric, MD; Robert Archambault, MD; Francois Vincent, MD; Redouane Bettahar, MD; Marie Duclos, MD; Derek Wilke, MD; Luis Souhami, MD, FASTRO</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>21</td>
<td>Joncarlos Anderson, MS  Vanderbilt-Ingram Cancer Center  NCCN Member Institution</td>
<td>Hydrogel Slope and Optimization of Prostate-Rectal Hydrogel Placement</td>
<td>Anne Rajkumar-Calkins, MD; Andres Frias, BS; Neil Newman, MD; Eric T. Shinohara, MD, MSCI; Austin N. Kirschner, MD, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>22</td>
<td>Huy Quoc Nong, MD  Methodist Dallas Medical Center</td>
<td>A Case Series of Male Breast Cancer Patients at Methodist Dallas Medical Center</td>
<td>Vasu Moparty, MD; Kimberly Rodriguez, BS; Alisha Manhas, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>23</td>
<td>Jeffrey Zhong, BS  Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute  NCCN Member Institution</td>
<td>Racial Differences in Outcomes of Osimertinib in Patients with EGFR-positive Non-Small Cell Lung Cancer in a Real World US Population</td>
<td>Jaime Abe Perez, PhD; Annie Liang Zhang, MD; Debora Bruno, MD, MS; Melinda Laine Hsu, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>24</td>
<td>Sang Chau, PharmD, BCOP  New Century Health</td>
<td>Accelerating Adoption of Hypofractionation in Breast Cancer Through Clinical Pathways and Peer Review</td>
<td>Mark Lorson, PharmD; Dalissa Kelly, PharmD; Casey Stockman, PharmD; Andrew Hetler, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines; Oncology Research Program</td>
</tr>
<tr>
<td>25</td>
<td>Nezha Tawfiq  Ibn Rochd University Hospital Center</td>
<td>Patient Satisfaction with Electronic Health Records: Results From a Survey of Moroccan Patients in Mohammed VI Oncology Center</td>
<td>Maryam Zaoui; Mouna Boughafour; Tarek Chekrine; Zineb Bouchbika; Nadia Benachkoun; Hassan Jouhadi; Souha Sahraoui; Abdellatif Benider</td>
<td>Bioinformatics/Information Technology Sciences</td>
</tr>
<tr>
<td>26</td>
<td>Emily Skotte, DNP, MSN  Vanderbilt-Ingram Cancer Center  NCCN Member Institution</td>
<td>Improving Multidisciplinary Thoracic Tumor Board with a Case Submission Tool</td>
<td>Wade Iams, MD, MSCI; Fabien Maldonado, MD; Rob Lentz, MD; Heather Jackson, PhD; Ty Williams, DNP, CNE</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>27</td>
<td>Annie L. Zhang, MD  Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute  NCCN Member Institution</td>
<td>Demographic Changes of Expanded 2021 Lung Cancer Screening Guidelines in a Large National Database</td>
<td>Jaime Abraham Perez, PhD; Melinda Hsu, MD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>28</td>
<td>Zachary Veitch, MSc, MD, FRCP  Royal Victoria Hospital</td>
<td>Impact of the COVID Pandemic on Oncology Education, Mentorship, and Networking - A National Survey</td>
<td>Jessica L. Conway, MD, FRCP; Giulio Di Diodato, MD, FRCP; Jennifer Croke, MD, FRCP</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>#</td>
<td>Presenting Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>----</td>
<td>----------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>29</td>
<td>Nguyen H. Tran, MD</td>
<td>MC200402-Single-Arm Phase 2 Study of the FGF18 Inhibitor Fututamibib in Combination with Pembrolizumab in Patients with FGF19 Expressing Advanced or Metastatic Hepatocellular Carcinoma</td>
<td>Joseph J. Larson, MS; Fang-Shu Ou, PhD; Amit Mahipal, MD; Shalene A. McCue, BS; Rondell R Graham, MBBS; Martin E. Fernandez-Zapico, MD; Alexander Revzin, PhD; Lionel A. Kankeu Fonkoua, MD; Lynn M. Flickinger, MA; Sean P. Cleafy, MD; Tanios S. Bekaiy-Saab, MD; Mitesh J. Borad, MD; Robert R. McWilliams, MD; Aminah Jato, MD; Wen Wee Ma, MBBS</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>30</td>
<td>Lincy Lai, PharmD, PhD</td>
<td>Evaluation of Patients with Multiple EGFR Genomic Tests in the Metastatic NSCLC Setting</td>
<td>Anna O. Williford, PhD; Dana E. Milne, PhD; Mark S. Walker, PhD</td>
<td>Correlative/Genomic</td>
</tr>
<tr>
<td>31</td>
<td>Amy Gallagher, PsyD, MSHCT</td>
<td>Committing to Resiliency: Transforming Burnout to Resilience at a National Cancer Institute (NCI) Comprehensive Cancer Center</td>
<td>Amy Case, MD, FAAHPM</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>32</td>
<td>Nicole Princic, MS</td>
<td>Real-World Analysis Examining Cost of Early Disease Progression among Patients with Epidermal Growth Factor Receptor Mutated Metastatic Non-Small Cell Lung Cancer</td>
<td>Elizabeth Marrett, MPH; Wingham Jacqueline Kwong, PharmD, PhD; Donna McGinnis, BS; Hana Schwartz, MS; Janikarman Subramanian, MD, MPH</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>33</td>
<td>Patrick Heckman, DO</td>
<td>Oncologists’ Perspectives on Metastatic Hormone Sensitive Prostate Cancer Management</td>
<td>Donglin Yan, PhD; Xitong Zhou, PhD; Zin Myint, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>34</td>
<td>Dariusz Uczkowski, MD</td>
<td>Treatment of HER2+ Breast Cancer: A Retrospective of Disease Progression With Loss of HER2 Amplification on Residual Disease After Neoadjuvant Treatment in a Community Hospital Setting</td>
<td>Arunabh Sekhri, MD; Shilpi Gupta, MD; Leah Gendler, MD; Krzysztof Miskiewicz, MD; Miles Levin, MD; Bonni Guerin, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>35</td>
<td>Adam C. Powell, PhD</td>
<td>Lung Cancer Treatment Utilization Trends: 2019-2021</td>
<td>Logan Horrell, MA; James W. Long, BSBA; Amin J. Michaili, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>36</td>
<td>Shane Burke</td>
<td>A Retrospective Review of Myelodysplastic Syndrome Management (MDS) at Watson Clinic LLP: From Diagnosis to Primary Course of Treatment</td>
<td>Galina Vugman, MD; Noreen McGowan, RN, BSN; CRCC; Michelle Sharratt, RN, BSN, CRCC</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>37</td>
<td>Elchin B. Mansurov, PhD</td>
<td>Why Did 560 Azerbaijan Population Women have De Novo Stage IV Breast Cancer?</td>
<td>Jamil A. Aliyev; Sewin J. Rahimzade, PhD; Leylah Khanum A. Melkova, PhD; Konul S. Mardanova, MD; Turkan E. Mansurova, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>38</td>
<td>Ting Hu, BS</td>
<td>The Diagnostic Value of Intraoperative Ultrasonography for the Diagnosis of Colorectal Cancer Liver Metastases</td>
<td>Huifang Li, MS; Chuang Peng, MS; Xingzhang Long, BS; Xu Han, MD, PhD; Shangman Yang, BS; Rahui Zou, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>39</td>
<td>Jiebai Zhou</td>
<td>Expression of PD-L1 Through Evolution Phase From Pre-Invasive to Invasive Lung Adenocarcinoma</td>
<td>Huo Lin; Zheng Ni; Rongkui Luo; Dawei Yang; Mingxiang Feng; Yong Zhang</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>40</td>
<td>Sarah Khan, MD</td>
<td>A Rare Case of Intrabuticular Cytosplasmic AL Amyloidosis in a Patient Without Multiple Myeloma</td>
<td>Vijay Ketan Reddy, MD; Ekaterina Proskurikova, MD; Pam Khosla, MD; Shan-Ching Ying, MD; Haoilang Xu, Xu</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>41</td>
<td>Hannah Yoo, BA</td>
<td>The Role of Smad4/TGFβ Signaling in the Tumor Progression from Intraductal Papillary Mucinous Neoplasia (IPMN) to Pancreatic Ductal Adenocarcinoma (PDAC)</td>
<td>Anna Means, PhD</td>
<td>Pre-Clinical Oncology</td>
</tr>
<tr>
<td>42</td>
<td>Javier Diaz-Santos, MD, MScEng</td>
<td>Central Location as Risk Factor for Poor Prognosis in Glidoblastoma: Definitive Results of the Descriptive and Survival Analysis of the MOWGLI Project</td>
<td>Cristina Garcia-Gonzalez, MD; Antonio Rueda-Dominguez, MD, PhD; Jose Manuel Jerez-Aragones, MSc, PhD; Eva Fragero-Blesa, MD, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>43</td>
<td>Mingxiang Feng</td>
<td>SPPI1 Regulated EMT in the Evolution from Pre-Invasive to Invasive Lung Adenocarcinomas as Dynamic Network Biomarker</td>
<td>Dawei Yang; Yong Zhang</td>
<td>Bioinformatics/Information Technology Sciences</td>
</tr>
<tr>
<td>44</td>
<td>Jiwesh Sharma, MD</td>
<td>Aligning NCCN Criteria With Testing Workflows Using a Novel Database Application (Criterion*)</td>
<td>Rena J. Varzio, CGC, MBA; Tawanna St. Lewis, CGC; Cheryl Reeves, CGC; Pranav Mukund, BS; Neal Sharma, MD; Morgan Tolley, BS; John Tan, MD, PhD; Poornam Sharma, PhD; Rekha Sharma, BS</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>45</td>
<td>Andres Garcia, MD, MSc</td>
<td>Electrocardiographic Findings in Cancer Patients Receiving Chemotherapy From the Colombian Coffee Triangle Region</td>
<td>David Medina, MD; Alejandra Palacio, MD, MSc; Andres Vallejo, MD; Luz Adriana Diaz, MD; Juan Dario Franco, MD; Tatiana Taborda, MD; Maria Jose Rojas, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>#</td>
<td>Presenting Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>----</td>
<td>------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>46</td>
<td>Przemyslaw Twadowski, MD</td>
<td>Cardiovascular Event Risk Following Androgen Deprivation Therapy Initiation By Personal History of Cardiovascular Events</td>
<td>Stuart Atkinson, MBChB; Deborah Boldt-Houle, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>47</td>
<td>Maria Philip, MBBS</td>
<td>Clinical Outcomes of Radical Radiotherapy With or Without Chemotherapy in Inoperable Locally Advanced Squamous Cell Carcinoma of Oral Cavity</td>
<td>Jomon Raphael, MBBS, DMRT, MDRT; Febin Antony, MBBS, MDRT; Rajkhrisha B.; Matthew Varghese K.</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>48</td>
<td>Julia Bielanin, BS, BA</td>
<td>Optimal Interval Between Immune Therapy and Targeted Therapy with Sotorasib in Patients with KRAS G12C Mutant Non-Small Cell Lung Cancer</td>
<td>Wade T. Iams, MD, MSCI; Heidi Chen, PhD; Amanda Case, PharmD; BCPS; BCPP</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>49</td>
<td>Vikas Sankar Kottareddygari, MBBS, MS, MCh</td>
<td>Should Worst Pattern of Invasion Be Considered an Independent Adverse Risk Feature in Oral Squamous Cell Carcinoma?</td>
<td>Rupanita Biswal, MBBS, MD; Pradyumma Kumar Sahoo, MBBS, MS; DrNB; Amitabh Jena, MBBS, MS; Sangram Keshari Panda, MBBS, MS; DrNB; Sudam Sadangi, MBBS, MS; MCh; Debaluhi Mohapatra, MBBS, MD; Vikas Sankar Kottareddygari, MBBS, MS, (MCh)</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>50</td>
<td>YiBo Xi, PhD</td>
<td>Electronic Cigarette Exposure on the Growth and Metastasis of Oral Squamous Cell Carcinoma</td>
<td>Man Jia, BS; Kien Pham, PhD; He Wang, PhD, MD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>51</td>
<td>Saroj Sah, MBBS</td>
<td>A Prospective Interventional Study to Assess the Response of Systemic Chemotherapy in Aggressive, Recurrent Giant Cell Tumor</td>
<td>Mohit Dhingra, Amrit Sehrawat; Sonal Saran</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>52</td>
<td>Erica Fortune, PhD</td>
<td>COVID-19 Impact and Psychosocial Well-Being Among Adults Living with Cancer: A Longitudinal Analysis</td>
<td>Victoria G. Morris, PhD; Caroline Lawrence, BS; Alexandra K. Zaleta, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>53</td>
<td>Mackenzie Taycher, PhD</td>
<td>Pooled Outcomes of Anti-BRAF Agents in Advanced Stage Colorectal Cancer</td>
<td>Ankita Aggarwal, PhD; David Tabagari, PhD; Ujaa Nagadia, PhD; Sai Gajagowini, BS; Venkata Vosuri, PhD; Kushal Naha, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>54</td>
<td>Karen Wonders, PhD</td>
<td>The Benefits of a Clinically Based Individualized Exercise Oncology Program on Health Care Utilization in Patients with Malignancies</td>
<td>Jay K. Harness, MD; Arthur G. Lerner, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>55</td>
<td>Karl D. Lewis, MD</td>
<td>Health-Related Quality of Life in Patients With Metastatic Basal Cell Carcinoma Treated With Cemiplimab: Analysis of a Phase 2 Open-Label Clinical Trial</td>
<td>Timothy J. Inocencio, PharmD, PhD; Ruben G.W. Quek, PhD; Patrick R. LaFontaine, PharmD, PhD; Zeynep Eroglu, MD; Anne Lynn S. Chang, MD; Cristina Ivanescu, PhD, LNMb; Alexander J. Stratigos, PhD; Ketty Peris, MD; Aleksandar Sekulic, MD, PhD; Matthew G. Fury, MD, PhD; Chieh-I Chen, MPH</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>56</td>
<td>Ze Cong, PhD, MS</td>
<td>Extensive and Dynamic Signs and Symptoms Prior to Cancer Diagnoses</td>
<td>Xiangyang Ye, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>57</td>
<td>Krishna Desai, MD</td>
<td>Isovindoleb as a Novel Treatment for Patients with Isocitrate Dehydrogenase-1 Positive Advanced Colon Cancer</td>
<td>Kristal Pereira, MD; Akhil Jain, MD; Sabah Iqbal, MD; Rajesh Thirumaran, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>58</td>
<td>Kamal Taneja, BA</td>
<td>Reasons for Lung Cancer Patients to Present to the ED</td>
<td>Steven Chen, BA; Kevin Metz, BS; William Benedict, BS; Karan Patel, BS</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>59</td>
<td>Marwa Abdelsalam, MBBS</td>
<td>Can Telemedicine Use Affect Oncologists’ Workload in the Arab World?</td>
<td>Saeed Shaaban, MD; Ayman Hanafy, MD; Riham H. AbdelAziz, MD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>60</td>
<td>Anuraag Kansal, PhD</td>
<td>The Potential Clinical Impact of a Multi-Cancer Early Detection Test for Individuals With Missing Cancer Stage Information</td>
<td>Alissa Shaul, MPH; Weicheng Ye, MPH; Anurag R. Kansal, PhD; A. Mark Fendrick, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>61</td>
<td>Liyi Bai, MD</td>
<td>A Novel Semi-Supervised Learning Algorithm for Prognosis-Oriented Classification and Biomarker Identification of Colorectal Cancer</td>
<td>Fanqin Bu, PhD; Xiangji Li, PhD; Xiaohan Yang, MD; Shuitian Zhang, PhD; Li Min, PhD</td>
<td>Bioinformatics/Information Technology Sciences</td>
</tr>
<tr>
<td>62</td>
<td>Himil Mahadevia, MD</td>
<td>An Unusual Case Presentation of Severe Idiopathic Multicentric Castelman Disease (IMCD)</td>
<td>Ammar Al-Obaidi, MD; Ujwal Madan, MD; Furha Cossor, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>#</td>
<td>Presenting Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>-----</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>63</td>
<td>Kenneth Chian, BS The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute NCCN Member Institution</td>
<td>Baseline Neutrophil to Lymphocyte Ratio and its Change Over Time Predict Overall Survival in Metastatic Non-Small Cell Lung Cancer Patients Who Received First Line Pembrolizumab Therapy</td>
<td>Mingjia Li, MD; Songzhu Zhao, MS; Saira Farid, MBBS; Timothy Gauntner, DO, PhD; Daniel Spakowicz, PhD; Lan Wei, PhD, MS; Austin Secor, BS; Evelyn Goodyear, BS; Panthib Das, MD; Kai He, MD, PhD; Asrar Alahmadi, MBBS; Regan Memmott, MD, PhD; Jacob Kaufman, MD, PhD; Carolyn Presley, MD; Peter Shields, MD; David Carbone, MD, PhD; Greg Ottesen, MD; Dwight Owen, MD, MS</td>
<td>Correlative/Genomic</td>
</tr>
<tr>
<td>64</td>
<td>Naleen Raj Bhandari, BPharm, MS, PhD Eli Lilly and Company</td>
<td>Characteristics and Outcomes of Patients Treated with Selpercatinib in the Real-World: A Retrospective Study Using US Claims Databases</td>
<td>Neha Bansal, MA; Chi-Hei Duann, MD; Anasofia Afonso, PhD; Shien Zheng, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>65</td>
<td>Shristi Upadhay Banskota, MBBS University of Nebraska Medical Center College of Medicine</td>
<td>Diagnosis of Metastatic Non-Small Cell Lung Cancer During Hospitalization: Missed Opportunity for Optimal Supportive Care?</td>
<td>Conor Houlihan, MD; Jonathan Q. Trinh, MD; Samia Asif, MBBS; Omar Abughanimeh, MBBS; Benjamin A. Teply, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>66</td>
<td>Kelly M. Smith, MD Abramson Cancer Center at the University of Pennsylvania NCCN Member Institution</td>
<td>Improving Management of Treatment Side Effects Through Chemotherapy Care Kit Delivery in Vietnam</td>
<td>NA</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>67</td>
<td>Natasha Mitchner, PhD Academy for Continued Healthcare Learning</td>
<td>Nurse Navigators Charted A Course for Equitable Care in Multiple Myeloma: Simplifying OI to Measure the Impact of Accredited Education</td>
<td>Amy Pierre, RN, MSN, ANP-BC; Vanessa Senatore, BS; Christine Hofmeyer, MS</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>68</td>
<td>Kelly E. McCann, MD UCLA Jonsson Comprehensive Cancer Center NCCN Member Institution</td>
<td>Real-World Use of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer Following Prior Ado-trastuzumab Emtansine (T-DM1) or Dual HER2 Blockade with Pertuzumab Plus Trastuzumab</td>
<td>Nina Ostreichner, PhD; Christopher G. Rowan, PhD; Gregory A. Vidal, MD, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>69</td>
<td>Nicole Nardella, MS, BS Moffitt Cancer Center NCCN Member Institution</td>
<td>Pancreatic Cancer: The Impact of Early Connectivity and Coordination of Care on Retention and Time to Treat</td>
<td>Matt Adams, BS; Anjali Mahapatra, BA; Diana Castillo, MA; Sarah Hoffer, MD; Dae Won Kim, MD; Jason Fleming, MD; Pamela Hodul, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>70</td>
<td>Ji Young Kwon, MD Kyung Hee University Hospital</td>
<td>Risk Factors and Prognosis of Stroke in Gynecologic Cancer</td>
<td>Jeong Min Song, MD; Young Shin Chung, MD; Kwang-Beom Lee, MD, PhD; Jong-Min Lee, MD, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>71</td>
<td>Tasleem J. Padamsee, PhD The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute NCCN Member Institution</td>
<td>Patient Awareness of Elevated Breast Cancer Risk After Routine Screening Mammogram and Risk Notification</td>
<td>Rachel Mason, MPH; Anna Muraveva, PhD; Wilson S. Figueroa, PhD; Paige A. Swinehart-Hord, BS; Steven Kalister, MHA; Sagar Sardesai, MD; Bushra Siddiqi, MD; Jeffrey Hawley, MD; Clayton Taylor, MD; Doreen Agnese, MD; Hayley Cissmaching, MS, CGC; Kevin Sweet, MS, LGCC; Noel Huber, BRST; Heidi Basting, MS, BSN</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>72</td>
<td>Matt Adams, BS Lake Erie College of Osteopathic Medicine</td>
<td>How Pancreatic Patients Choose their Cancer Center: An Analysis of Factors That Influence Retention</td>
<td>Nicole Nardella, MS; Anjali Mahapatra, BA; Diana Castillo, MA; Sarah Hoffer, MD; Dae Won Kim, MD; Jason Fleming, MD; Pamela Hodul, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>73</td>
<td>Athena Puski, MS, LGC University of Iowa Hospitals and Clinics</td>
<td>Real World Data on the Implementation of a Hereditary Hematological Myeloid Malignancy Workflow: Experience of a Single Academic Medical Center</td>
<td>Athena Puski, MS; Jennifer L. Stinson, MS; Nicole Huser, MS; Madeline VanDerGraaf, MS</td>
<td>Correlative/Genomic</td>
</tr>
</tbody>
</table>
## General Poster Session II

Hosted by NCCN Oncology Research Program (ORP)

**Session II | Saturday, April 1**

**Breakfast 7:30 - 8:30 AM | Morning Break 10:25 - 10:45 AM**

**Lunch 12:00 - 1:15 PM | Afternoon Break 3:25 - 3:45 PM**

### Finders and Sponsors

- Lunch
- Breakfast 7:30 - 8:30 AM
- Session II | Saturday, April 1
- Hosted by NCCN Oncology Research Program (ORP)
- General Poster Session II

### Presenting Author and Institution

<table>
<thead>
<tr>
<th>#</th>
<th>Presenting Author and Institution</th>
<th>Title</th>
<th>Co-Authors</th>
<th>Category</th>
</tr>
</thead>
</table>
| 74 | Christopher D’Andrea, PA-C  
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute  
NCCN Member Institution | An APP-Run Lymphadenopathy Clinic: The Cleveland Clinic Experience | Stacy Mathews, CNP; Brian Hill, MD, PhD | Clinical Oncology |
| 75 | Alexandrina Balanean, MPH  
Cardinal Health, Inc. | Uterine Cancer (UC) on the Rise in the United States (US): One of the Largest Racial Disparities in Oncology | Angelica Falkenstein, PhD; Yolaine Smith, PhD; Bruce Feinberg, DO | Outcomes and Health Services Research |
| 76 | Jonas M. Congelli, RPh  
Hematology Oncology Associates PC | Do EHR-embedded Clinical Decision Support Tools Reduce Variation in Care? A Pre and Post-Implementation Comparison of Regimen Ordering Variation at a Multi-Site Community Cancer Clinic | Heather Lewin, APRN, MSN; Gregory Calip, PharmD, MPH, PhD; Marcello Ricottone, PharmD, BCOP; Shawn Huda, PharmD, BCDP; Taylor Dias-Foundas, PharmD, BCDP; Rebecca Maniago, PharmD, BCDP | Quality Improvement |
| 77 | Neethi Dasu, DO  
Jefferson Health - New Jersey | Analyzing Trends in the Incidence and Mortality of Esophageal Cancer in the United States: A 15-Year Population-Based Study | Kirt Dasu, BA; Jason John, DO; Yaser Khalid, DO; Brian Blair, DO; Lucy Joo, DO; C. Jonathan Foster, DO | Epidemiology/Risks/Prevention |
| 78 | Joseph Vento, MD  
Vanderbilt-Ingram Cancer Center  
NCCN Member Institution | Precision Oncology: Integrating Structured Genomic Data into the Electronic Health Record via the EPIC™ Genomics Module | Travis Osterman, DO, MS | Bioinformatics/Information Technology Sciences |
| 79 | Alexandrina Balanean, MPH  
Cardinal Health, Inc. | Oncologists’ Perceptions of a Novel Superoxide Dismutase Mimetic (Avasopasem Manganese) for Treating Severe Oral Mucositis in Patients with Locally Advanced Head and Neck Cancer | Brooke Leon, BA; Yolaine Jeune-Smith, PhD; Chukwuechemaka Ikpeazu, MD, PhD, MBA; Bruce Feinberg, DO | Best Practices in Implementation and Use of Clinical Practice Guidelines |
| 80 | Chin-Hsuan Huang, MD  
Taipei Medical University Hospital | The Impact of Dysbiosis Agents on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Melanoma Patients: A Systematic Review with Meta-Analysis | Andrea S., MD; Yi-Nyo Kang, MA; Yu Chang, MD; Tsu-Hsien Wang, MD; Kuan-Yu Chi, MD | Clinical Oncology |
| 81 | Muhammad Zain Farooq, MD  
Moffitt Cancer Center  
NCCN Member Institution | Safety Profile of Sonic Hedgehog Inhibitors in Basal Cell Carcinoma: A Systematic Review | Mishal Shan Siddiqui, MBBS; Syed Ali Farhan, MD; Mahima Khatri, MBBS; Syed Harma Bin Waqar, MD; Saad Khalid, MBBS; Ankit Mangla, MD | Clinical Oncology |
| 82 | Neethi Dasu, DO  
Jefferson Health | Outcomes of Patients With Pancreatic Cancer Undergoing Duodenal Stent Placement: A Population-Based Study | Kirti Dasu, BA; Jason John, DO; Yaser Khalid, DO; Lucy Joo, DO; Brian Blair, DO; C. Jonathan Foster, DO | Outcomes and Health Services Research |
| 83 | Tarun Chowdary Gogineni, MCh  
GSL Medical College and General Hospital | Oral Cancer Screening Among the Rural Indians — A Community Based Prospective Study | NA | Epidemiology/Risks/Prevention |
| 84 | Akhil Jain, MD  
Mercy Fitzgerald Hospital | Does Anemia contribute to Increased Risk of Adverse Outcomes in Cancer Patients with Venous Thromboembolism- A Longitudinal Study from National Representative Population? | Sohiel Deshpande, MD; Sabah Iqbal, MD; Krishna Desai, MD; Aisha Sultanah, MD; Kristal Perenia, MD; Aisha Abdul Sattar, MD; Mohammad Hamza, MD; Bohdan Baralo, MD; Rajesh Thirumaran, MD | Clinical Oncology |
| 85 | Veronika Patsko, MD  
National Cancer Institute of Ukraine | Volatile Organic Compounds Released by Gastric Tissues as Potential Biomarkers of Gastric Cancer | Pawel Mochalski; Marius Leja, MD, PhD, MBA, AGAF; Andri Lukashenko, MD, PhD, DMSc; Daria Iefanska-Wolak; Linda Mecmale, MD; Clemens Ager; Agnieszka Król; Chris A. Mayhew, Gidi Shani, PhD; Hossam Haick, PhD, MSc | Pre-Clinical Oncology |
| 86 | Akhil Jain, MD  
Mercy Fitzgerald Hospital | Impact of Socio-Economic Disparity on Survival of HER 2 Neu (+) Breast Cancer Brain Metastasis Patients with Chemotherapy: A SEER Study | Rikeen Dhaduk, MPH; Sagar Patel, MD; Udhayvir Singh Grewal, MD | Clinical Oncology |
<table>
<thead>
<tr>
<th>#</th>
<th>Presenting Author and Institution</th>
<th>Title</th>
<th>Co-Authors</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>87</td>
<td>Edmund W. Tai, MD</td>
<td>Sutter Health</td>
<td>Re-World Dosing Patterns in Patients with Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated with Brigatinib in the Front-Line (FL) Setting in the United States: A Claims Database Analysis</td>
<td>Huamao Lin, PhD; Yanyu Wu, PhD; Yin Wan, MS; Magdaliz Gorritz, MPH; Xiaoyou Zhou, MS; Chi-Chang Chen, PhD; Yuanbin Chen, MD, PhD</td>
</tr>
<tr>
<td>88</td>
<td>Georgio Medawar, MD</td>
<td>Roger Williams Medical Center</td>
<td>Improving Hematology-Oncology Education in Internal Medicine Residency - A Single Institution Quality Improvement Project</td>
<td>Jessica Khoury, MD; Antoine Salloum, MD; John Miskovsky, MD</td>
</tr>
<tr>
<td>89</td>
<td>Sabine Oskar, PhD, MPH</td>
<td>Merck &amp; Co, Inc.</td>
<td>Real-World Study of Biomarker Testing and Treatment Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in the United States (US): A Physician Survey</td>
<td>Jeri Kim, MD, MBA; Alicia Gayle, PhD; Chloe Middleton-Dalby, MRes; Hirami Aggarwal, PhD</td>
</tr>
<tr>
<td>90</td>
<td>Fabrizio Mavilla, MD</td>
<td>University of Pisa School of Medicine and Surgery</td>
<td>Update From the Dedalo Protocol: An Integrated Approach to MRD in CLL Patients Receiving Venetoclax Plus Ritusimab</td>
<td>Francesco Ghio, MD; Giulia Cervetti, MD; Claudia Barati, MD; Gaspare Tandredi, MD; Dimitri Dardanis, MD; Eliza Mazzenzini, MD; Pietro Rossi, MD; Paola Sammuri, BS; Valentina Guarri, MD; Clara Bono, BS; Susanna Grassi, BS; Edoardo Benedetti, MD; Sara Galimberti, MD</td>
</tr>
<tr>
<td>91</td>
<td>Amye J. Tevaarwerk, MD</td>
<td>Mayo Clinic Comprehensive Cancer Center NCCN Member Institution</td>
<td>Using the Electronic Health Record (EHR) to Capture Structured Oncology Data in Real-Time at the Point-of-Care: A Mayo Clinic Comprehensive Cancer Center (MCCCC) Pilot Study</td>
<td>Elizabeth S. Harlos, BS; Matthew J. Maurer, DMSc; Heather L. Vanbebber, BSN; Eli J. Misel, AAB, BS; Sacha A. Nelson, MS, PMP; Sara J. Holton, AS, BS; CTR; Abigail L. Stockham, MD; Tufa C. Haddad, MD; Steven R. Alberts, MD, MPH; Robert R. McWilliams, MD; Sumithra J. Mandlekar, PhD</td>
</tr>
<tr>
<td>92</td>
<td>Begum Bahar Yilmaz, MD</td>
<td>Istanbul Basaksehir Cam and Sakura State Hospital</td>
<td>The Role of miRNA 21 and miRNA 101 in Diagnosis, Prognosis and Survival of Laryngeal Cancer</td>
<td>Sinem Durmus, PhD; Yetkin Zeki Yilmaz; Murat Yener; Irfan Papila; Hafize Uzun</td>
</tr>
<tr>
<td>93</td>
<td>Anne Shah, PhD</td>
<td>AstraZeneca Pharmaceuticals, LP</td>
<td>Physician Preferences on Biomarker Testing in Newly-Diagnosed metastatic NSCLC Patients Who had Insufficient Tumor Tissue</td>
<td>Jon Apple, PharmD; Gabriela Burgos, MPH; Josh Larkin, MSc; Jesse Cohn, PhD; Janelle Cambron-Mellott, PhD; Emily Mulvihill, MBA</td>
</tr>
<tr>
<td>94</td>
<td>Chunlan Chang, PhD</td>
<td>Kyowa Kirin North America</td>
<td>Real-World Combination Use of Mogamulizumab with Other Therapies Among Patients with Mycosis Fungoides and Sezary Syndrome</td>
<td>Jackson Tang, PhD; Chunlan Chang, PhD; Zhishui Zheng, MS; Takeshi Takahashi, PhD; Takanobu Nomura, PhD; Robert Ristuccia, PhD; Esile Dennis, MBChB, FCP</td>
</tr>
<tr>
<td>95</td>
<td>Mona H. Cai, PhD</td>
<td>AbbVie, Inc.</td>
<td>Non-Squamous, Metastatic Non-Small Cell Lung Cancer: Retrospective C-Met Overexpression Testing, Patient Characteristics, and Treatment Patterns</td>
<td>Yookyung Christy Choi, PharmD, PhD; Athan Vasilopoulos, PhD; Alexander Liede, MSc, PhD; Sidney S. Lindsey, MPH; Leon Raskin, MSc, PhD; MBA; Ethan Truong, BS; Jeremy Fricker, BS; Stephen B. Gruber, MD, PhD; MPh; Peter J. Ansell, PhD</td>
</tr>
<tr>
<td>96</td>
<td>Daniel Olson, MD</td>
<td>University of Chicago Comprehensive Cancer Center</td>
<td>Immune Checkpoint Inhibitor (ICD) Treatment After Progression on Anti—PD-1 Therapy in Advanced Melanoma: A Systematic Review of the Literature</td>
<td>Brian Gastman, MD; Alicia Rowell, BA; Madan Jagasia, MD; Parameswaran Hari, MD; Wen Shi, MD, PhD; Kendall Stevinson, MD; Katy K. Tsai, MD</td>
</tr>
<tr>
<td>97</td>
<td>Alexandra Mara, MD</td>
<td>Duke Cancer Institute NCCN Member Institution</td>
<td>Creating a Fellowship Curriculum: Clinical Trial Patient Conversations</td>
<td>Ryan Rader, MD; Carma Bylund, PhD; Susan Eggy, PhD; Elisa Weiss, PhD; Leah Zumita, MS, RN; Andrea Silinger, MD, Daphne Friedman, MD</td>
</tr>
<tr>
<td>98</td>
<td>Emma Kar, BS</td>
<td>The University of Arizona College of Medicine Phoenix</td>
<td>Bimodal Distribution of Osteosarcoma: A Thing of the Past—Comparative Analysis from Surveillance, Epidemiology, and End Results (SEER) and National Inpatient Sample (NIS)</td>
<td>Amrit Ammanamanchi, BS; Arya Mishra, MS; Jialing Lang, MS; Bijun Kannadath, MBBS, MS</td>
</tr>
<tr>
<td>99</td>
<td>Vihbhy Pareek, MD, DNB</td>
<td>CancerCare Manitoba</td>
<td>Risk of Second Malignancy Among Non-Metastatic Seminoma Patients Treated with Radiation Therapy and Chemotherapy in Manitoba</td>
<td>Marin Adu-Quaye, MD; Justin Owen, FRCP; Oliver Bucher, MS; Aldrich Ong, FRCP; Arbinder Dubey, FRCP; Bashir Bashir, FRCP; Rashmi Kou, FRCP</td>
</tr>
<tr>
<td>100</td>
<td>Rutika Mehta, MD</td>
<td>Moffitt Cancer Center NCCN Member Institution</td>
<td>Disease Burden and Treatment Patterns in Patients Diagnosed With HER2- Metastatic Gastric/Gastroesophageal Junction Cancer (mGEJC)</td>
<td>Rupali Fuldeore, MS; Hongbo Yang, PhD; Wei Song, PhD; Adina Zhang, MS; Sophie Gao, MS; Christopher Young, PhD; Bin Xie, PhD</td>
</tr>
<tr>
<td>101</td>
<td>Maria Cecilia Vieira, MS</td>
<td>Pfizer, Inc.</td>
<td>Patient and Provider Perspectives on How COVID-19 Impacted Melanoma Care Delivery</td>
<td>Laura Mesana, MS; Meaghan Roach, MPH; Rozanne Wilson, PhD; Nana Rezai, PhD; Maria Cecilia Vietra, MS; Suepattra G. May, MPH, PhD</td>
</tr>
<tr>
<td>#</td>
<td>Presenting Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>-----</td>
<td>----------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>102</td>
<td>Haifa Haj Abdallah, MD</td>
<td>Health Care Satisfaction Among Cancer Patients Undergoing Radiotherapy: A Tunisian Center Experience</td>
<td>Sabrine Tbessi, MD; Emma Boudhina, MD; Rym Zanzouri, MD; Samia Belaajouza, Pr; Nadia Bouzid, Pr; Sameh Tebra, Pr</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>103</td>
<td>Sarah McCaffrey, RN, ANP-BC, AOCNP</td>
<td>An APP Initiated Telehealth Visit to Reduce Oncology Patient Readmissions: Lessons Learned</td>
<td>Crystal Wolf, FAC; Paula Goldberg, RN, MSN; Margaret Faul, RN; Emily Pagel, RN, BSN; Alexandria Westerman, RN, BSN; Anna Comnas, RN, BSN; Bindya G. Patel, MD; Patricia Likkowski, MD; Olivia Aranha, MD, PhD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>104</td>
<td>Daniel Simmons, PharmD, MS</td>
<td>Clinical Characteristics and Outcomes of US Extensive Stage Small Cell Lung Cancer (ES-SCLC) Patients not Receiving Guideline Preferred Regimens</td>
<td>Yang Xiao, PhD; Corina Roca, MS; Zhuoxun Jiang, MS; Marije Boron, PharmD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>105</td>
<td>Megan Corbett, MSN, RN, NPD-BC, OCN</td>
<td>Evaluation of a Standardized Approach to Hypersensitivity/Infusion Reaction Management in a Large Ambulatory Oncology Center</td>
<td>Marylou Nesbitt, MS, RN; Bridget Scullion, PharmD; BCOP; Donna Marie Lynch, MSN; Mariana Castells, MD, MD; PhD; Yun Man, PharmD; Terri Jabaley, PhD, RN</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>106</td>
<td>Kavitha Nair, MSN</td>
<td>The Impact of Tailored Lean Approach in Optimization of Infusion Scheduling Process in an NCI Designated Cancer Center</td>
<td>NA</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>107</td>
<td>Ashley Schlafstein, MD</td>
<td>The Influence of Operability Status on Outcomes in Patients with T4a Larynx Cancer: An Institutional Experience</td>
<td>Subir Goyal, PhD; Ashley Aiken, MD; Jill Remick, MD; Nabil Saba, MD; James Bates, MD; Soumon Rudra, MD; Mark McDonald, MD; Azeem Kaka, MD; William Stokes, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>108</td>
<td>Yee-Jyh Chen, PhD</td>
<td>Stress-Related Biofeedback Responses after Reiki and Sound Healing Therapies for Breast Cancer Survivors</td>
<td>Claire Ostadi; Wayland Tseh, PhD; Kayla Wightman; Hawken V. Hass, BA; Tamara Link, DNP, FNP-BC</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>109</td>
<td>Carol-Ann Benn, MB, BCh</td>
<td>Targeted Axillary Dissection Post Primary Chemotherapy: Data Analysis from a Single Multidisciplinary Unit in South Africa</td>
<td>Bernado Rapoport, MD; Dominic Van Loggengerg</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>110</td>
<td>Kimberly P. Rogers, PhD</td>
<td>Emotional and Mental Health Support Needs of Adolescent and Young Adult (AYA) Colorectal Cancer Patients</td>
<td>Victoria G. Morris, PhD; Erica E. Fortune, Phd; Andrea Goodman, MSW; MPH; Kim Newcomer; Susan Pfau, MA, LMFT; Christine L. Sardo Molmenti, PhD, MPH; Cynthia A. Thomson, PhD, RD; Alan R. Veno, MD; FASC; Melissa F. Miller, PhD, MPH</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>111</td>
<td>Yolcar Chamorro, MS</td>
<td>Real-World Study of First-Line Treatment Patterns in HR+/HER2- Metastatic Breast Cancer (MBC) at a Tertiary Care Cancer Institute</td>
<td>Manmeet S. Ahluwalia, MD, MBA; Mun I. Rubens, MBBS, PhD; MPH; Siddhartha A. Venkatappa, MBBS, MPH; Andrew J. Belli, MPH; Nicholas Ritter, MBA; Ching-Kun Wang, MD; Reshma L. Mahtani, DO; Ana Sandoval Leon, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>112</td>
<td>Salwa Fathy, BS, MD, PhD</td>
<td>HDR-ICR Brachytherapy with Solo Anesthesia Administration as a Resource-Effective and Patient-Safe Method in Cancer Cervix</td>
<td>Umm Salma Mohammamed, MS; Mazen Al-Gaoud, BS; Nasser Al-Dhahani, FRCP; Maha Al-Aldini, FRACP</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>113</td>
<td>Vivek Yadala, MD</td>
<td>A Race Against Time in Cancer Diagnosis: A QI Study</td>
<td>Austin Rush, MS; Howide Eldib, MBBSch; Miranda van Tilburg, PhD; Mina Shemouda, MBBch</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>114</td>
<td>Zoran Gatalica, MD, DrSci</td>
<td>The Frequency of Androgen Receptor Splice Variant 7 (AR-V7) in Solid Tumors</td>
<td>Jess Hoag, PhD; David W. Hall, PhD; Fadel S. Alyaqoub, PhD; Susan Dombrowski, MD; Pawan Noel, PhD; Szabolcs Szlinger, PhD; Sameer Udhane, PhD; Min Wang, MD, PhD; Snehal G. Thakkar, MD; Gangi Basu, PhD</td>
<td>Correlative/Genomic</td>
</tr>
<tr>
<td>115</td>
<td>Pragya Rai, PhD</td>
<td>First-Line (1L) Systemic Therapy in Patients (pts) with Advanced Non-Small Cell Lung Cancer (aNSCLC) at Community Settings in the United States (US)</td>
<td>Pragya Rai, PhD; Yu-Han Kao, PhD; Diana Chirovsky, PhD; Ana Nunes, MD, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>116</td>
<td>Betsy J. Lahue, MPH</td>
<td>Assessment of Physician Treatment Preferences for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)</td>
<td>Katherine Gaburo, BA; Betsy Lahue, MPH; Kalatu Davies, PhD; Jon Ukropec, PhD; Monika Jun, MPH</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>117</td>
<td>Dominic van Loggengergen, MD</td>
<td>Digital Multidisciplinary Meetings Enable Regional Specialist Oncology Treatment</td>
<td>Carol Ann Benn, MBCH, FSC</td>
<td>Bioinformatics/Information Technology Sciences</td>
</tr>
<tr>
<td>118</td>
<td>Ernesto Munoz, MD</td>
<td>Extranoval Presentation of Double Hit High Grade B Cell Lymphoma</td>
<td>Allison Carilli, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>#</td>
<td>Presenting Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>-----</td>
<td>----------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>------------------------------------</td>
</tr>
<tr>
<td>119</td>
<td>Alison Roos, PhD, Illumina, Inc</td>
<td>Tissue and Liquid Biopsy Utilization in Advanced NSCLC in a Large Community Practice</td>
<td>Lucio Gordan, MD; Michael Diaz, MD; Anjan Patel, MD; Matthew Fink, MD; David Wenk, MD; John Jiang, PhD; Janice Tam, PhD; Prateesh Sathyain, PhD; Phil Felbo, MD</td>
<td>Correlative/Genomic</td>
</tr>
<tr>
<td>120</td>
<td>Anna Teschemaker, PhD, AstraZeneca Pharmaceuticals, LP</td>
<td>Real-World Duration of Venetoclax Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia (CLL/SLI)</td>
<td>Anna Teschemaker, PhD; Shweta Hakre, PhD; Jenny Tse, MD; Nazneen Fatima Shaikh, PhD; Yifan Gu, MS; Aimee Near, MPH</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>121</td>
<td>Margaret Kelsey Baron, MD, Huntsman Cancer Institute at the University of Utah, NCCN Member Institution</td>
<td>Mutational Landscape in Concurrent and Sequential Cases of Lymphoid Malignancy and CMMML</td>
<td>Ania Shestakova, MD; Tony D. Pomicter, MD; Justin Williams, MPh; Srinivas K. Tantravahi, MBBS; Am B. Patel, MD; Deborah M. Stephens, DO</td>
<td>Correlative/Genomic</td>
</tr>
<tr>
<td>122</td>
<td>Annette Hood, PharmD, Yale Cancer Center/Smilow Cancer Hospital, NCCN Member Institution</td>
<td>Real-World Frequency of ECHO Monitoring and Incidence of Anti-HER2 HER2+ Related Cardiac Events in HER2+ Breast Cancer Patients</td>
<td>Blerina Mukallari, PharmD; Jacqueline Majeski, PharmD; Lajos Pusztai, MD; Kerin Adelson, MD; Kejal Amin, PharmD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>123</td>
<td>Swathi Kanakamedala, DO, Northeast Georgia Medical Center Gainesville</td>
<td>Quality Improvement: Using a Multi-Modal Approach in Addressing Identified Barriers to Improve Lung Cancer Screening in Northeast Georgia — An Interim Report</td>
<td>Andina Caton, MSN, RN, OCN, CHPN; Shivang Umesh Dansak, MD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>124</td>
<td>Simran Polce, BS, Stony Brook University Renaissance School of Medicine</td>
<td>Evaluation of Adding Neck Dissection to N0 Head and Neck Cancer Patients</td>
<td>Dylan Jacob Cooper, BA; Husnearsa Rahman, MS; Nina Kohn, MS; A. Gabriella Wernicke, MS; MS; Louis Potters, MD; Bhupesh Parashar, MD, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>125</td>
<td>Haoran Li, MD, PhD, Huntsman Cancer Institute at the University of Utah, NCCN Member Institution</td>
<td>Tumor Transcriptomic Profile in Patients (pts) with Synchronous Versus Metachronous Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)</td>
<td>Jong Taek Kim, MD; Beverly Chigara, MD; Kamal Kant Sahu, MD; Georges Gebrail, MD; Shrutik Adidam Kumar, MD; Nishita Tripathi, MD; Nicolas Sayegh, MD; Vinay Matthew Thomas, MD; Umang Swami, MD; Neeraj Agarwal, MD; Benjamin L. Maughan, MD, PharmD</td>
<td>Correlative/Genomic</td>
</tr>
<tr>
<td>126</td>
<td>Kimberly Boldig, DO, University of Florida College of Medicine</td>
<td>Predictors of Delay for Initial Oncology Referral and Treatment at a Safety-NET Hospital: A Single Center Analysis</td>
<td>Steven Badami, MD; Abhinav Rohatgi, MD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>127</td>
<td>Riley Walton Jackson, MS, Stanford Cancer Institute, NCCN Member Institution</td>
<td>Adding Virtual Reality Mindful Exposure Therapy to a Cancer Center's Tobacco Treatment Offerings: An Acceptability Pilot Study</td>
<td>Choksi R.; Petro D.; Johnson M.; Vasudevan A.; English S.; Marielle Fares, PharmD; Gidley H.; Sura T.; Varughese P</td>
<td>Bioinformatics/Information Technology Sciences</td>
</tr>
<tr>
<td>128</td>
<td>Anupama Vasudeva, BDS, MPH, PhD, Integra Connect, LLC</td>
<td>Real-world Observations Show Beneficial Outcomes in Patients with NSCLC Treated with Pembrolituzumab for More Than 2 Years</td>
<td>Tony Hewitt, MBS; Heidi Simmons, PhD; Steve Thullier, PharmD; Benjamin Eckert, MS</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>129</td>
<td>Miai Jiang, PhD, Adaptive Biotechnologies Conquering Cancer Research Programation</td>
<td>Assessment of Sustained MRD Negativity and Reversion in Real-World Multiple Myeloma Patients Using NGS (clonoSEQ Assay)</td>
<td>Tony Hewitt, MBS; Heidi Simmons, PhD; Steve Thullier, PharmD; Benjamin Eckert, MS</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>130</td>
<td>Deepali Pandey, MBBS, University of Kentucky Markey Cancer Center</td>
<td>Disparities in Prostate Cancer Survival Outcomes in Appalachian Kentucky</td>
<td>NA</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>131</td>
<td>Hamid Emanekhoosh, MD, University of Wisconsin Carbone Cancer Center, NCCN Member Institution</td>
<td>Supporting the Capture of Structured Data for Patients with Cancer Using Cancer-Specific Note Templates</td>
<td>Cibele Carroll, MD; Chelsea Stetzel, BS; Jeffrey B. Pier, BS; Michael D. Lavitschke, BS; Daniel Mulkerin, MD; Mary E. Sesto, PT, PhD; Amye J. Tevaanwerk, MD</td>
<td>Bioinformatics/Information Technology Sciences</td>
</tr>
<tr>
<td>132</td>
<td>Luke Proctor, DO, Orlando Health Arnold Palmer Hospital for Children</td>
<td>Pediatric Metastatic Pulmonary Adenocarcinoma</td>
<td>Arjith Rathakrishnan, MD; Claudia Zapata, MD; Kanwar Anoop Kainaur, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>133</td>
<td>Isadora Alves Praxedes, Centro Universitario Mauricio de Nassau</td>
<td>Knowing the Lymphomas of the Legal Amazon: How Do They Differ?</td>
<td>Cinthya Oliveira Nascimento; Iane da Costa Scharff; Alexandre Carvalho Garcia; Guilherme Eler de Almeida; João Guilherme Ruiz Ferreira</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>134</td>
<td>Akshit Chitkara, MD, University of California Riverside School of Medicine</td>
<td>PD-1/PD-L1 Inhibitors in Advanced and Metastatic Esophageal Carcinoma: An Updated Meta-Analysis of Randomized Controlled Trials</td>
<td>Femina Patel, MD; Rushin Patel, MD; NUNA Anamika, MD; Rajat Thawani, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>#</td>
<td>Presenting Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>-----</td>
<td>---------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>135</td>
<td>Joy Ogunmuyiwa, MD, MPH</td>
<td>Dosimetric Comparison of Hypofractionation with Concomitant Boost versus Sequential Boost Following Breast-Conserving Surgery in Early Stage Breast Cancer Patients</td>
<td>Hanaan Habibulla, CMD; Haoyu Wang, MS; Onyinye Balogun, MD; Hani Ashamalla, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>136</td>
<td>Jessica Zhu, MD</td>
<td>Comparison of Modified Patient-Reported Paper G6 and EPIC G44 with Clinician Reported Standard G6 to Screen Frailty in Elderly Patients with Cancer</td>
<td>Diana Abbott, PhD; Corbin Eule, MD; Maksym Goryachok, BS; Theresa Tafaya, BS; Sarah Roberts, MS; Andrea Nederveld, MD; MPH; Hillary Lum, MD, PhD; Daniel Sherbenou, MD, PhD; Elizabeth R. Kessler, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>137</td>
<td>Hiffsa Taj, MD</td>
<td>Risk of Secondary Malignancies After Platinum-Based Chemotherapy in Testicular Seminoma Patients: A Population-Based Study</td>
<td>Ayman Qasrawi, MD; Zin Myint, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>138</td>
<td>Aaron W. Gehr, MPH</td>
<td>Effectiveness of a Provider Education Intervention for Increasing Human Papillomavirus Vaccine Uptake at Pediatric Clinics within a Safety-Net Health System</td>
<td>Rachel J. Meadows, PhD; Yan Lu, MPH, MBBS; Grace Maynard, MPH; Idara N. Akpan, MPH; Tanjila Taskin, PhD; Kimberly Fulda, DrPH; Divya Patel, PhD; Rohit P. Ojha, DrPH; Erika L. Thompson, PhD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>139</td>
<td>Hiral Patel, MD</td>
<td>Elevation in the Creatinine with Niraparib: True or False?</td>
<td>Amog Jayarangaih, MD; Siddhartha Kattamanchi, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>140</td>
<td>Mariana Novoa-Santos, MS</td>
<td>Patient-Level Barriers to the Global Care for Familial Adenomatous Polyposis: Lessons From a Large Brazilian Family</td>
<td>Débora de Paula Michelatto, PhD; Isabella Lopes Monleió, PhD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>141</td>
<td>Anand Singh, BS</td>
<td>Perceived Risk and Uptake of Healthy Lifestyle Behaviors for Breast Cancer Prevention Among High-Risk Women</td>
<td>Siri Tummala, BA; Tasleem J. Padamsee, PhD; Rachel Meadows, PhD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>142</td>
<td>Ana Carolina Tamayo Palacio, MD</td>
<td>Frequency of Hereditary Cancer Syndromes in Pediatric Patients: Experience in a Tertiary Care Children's Hospital in Mexico</td>
<td>Alejandra del Pilar Reyes de la Rosa, MD; MS; Romina Viveros Rodriguez, Rodrigo Moreno Salgado, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>143</td>
<td>FNU Anamika, MD</td>
<td>Interventional Pain Management in Outpatient Setting for Cancer Patients: A Review of Literature</td>
<td>Akshtil Chikara, MD; Anh-Tran Bui, DO; Quang Nguyen, MD; Anshia Adib, MD; Pramil Chenniyath, MD; Karamjeet Sandhu, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>144</td>
<td>John Isikia, MPH</td>
<td>Conventional Hydration versus Short Hydration for Reducing Chemotherapy Induced Nephrotoxicity (CIN) Among Adult Esophageal Cancer Patients at Uganda Cancer Institute, Mbarara Uganda: An Interventional Study</td>
<td>Idrine Kato, BPharm; Imelda Busingye, BSN; Semei Sekitene, MMed</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>145</td>
<td>Abdul Rahman Al Armashi, MD</td>
<td>Race &amp; Gender Specific Trends of Mortality from Hepatocellular Carcinoma in the United States, 1999 - 2020</td>
<td>Anas Al Zubaidi, MD; Apoorva Krishna Chander, MD; Dina Elantably, MD; Faris Hammad, MD; Kanchi Patell, MD; Mohamed Homeida, MD; Akram Alkreshi, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>146</td>
<td>Rym Zanzouiri Centre Hospitalier Universitaire Farhat Hached de Sousse</td>
<td>Dosimetric Assessment of 3-Dimensions Radiotherapy (3D-RT) and Intensity Modulated Radiotherapy (IMRT) for Flank Irradiation in Pediatric Patients with Wilms Tumor: Benefit-Risk Balance</td>
<td>Nadia Bouzid; Mohamed Souissi; Bawader Ameri; Raouf Hammouda; Syrine Ben Ghia; Sabrine Tbesbi; Samia Kanoun Belajour; Sameh Tegra</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>147</td>
<td>Alexis Bartley Paulson, MSN, ARPN</td>
<td>Electronic Health Record Alerts Compared to Chart Review for Lung Cancer Screening Eligibility</td>
<td>Lauren Hatcher, BA; Shanna Joyner; Sarah Valenti, MSN, ARPN; Kim Sandler, MD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>148</td>
<td>Mark Joshua Chang, DO</td>
<td>Effectiveness and Toxicity of Cetuximab with Concurrent RT in Locally Advanced Cutaneous Squamous Cell Skin Cancer: A Case Series</td>
<td>Wolfram Sarniowski, MD; Douglas Fife, MD; Mac Machan, MD; Raul Meoz, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>149</td>
<td>Sujan Badal, MD</td>
<td>Incidence &amp; Mechanisms of Coexisting Hematological Malignancies: Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia— A Retrospective Review</td>
<td>Mariam Alamgir, MD, MBA</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
</tbody>
</table>
Some treatments manage cancer. We’re out to cure it.

Our biggest goal is to stop cancer before it can adapt and evolve. That’s why we’re developing innovative personalized therapies, and other treatments to harness the body’s natural defenses. Everything we do gets us closer to a future where disease is a thing of the past. Learn more at www.janssen.com.
From the realization of risk to the moment of diagnosis, from finding care to staying informed and building your resources, we relentlessly advocate for all people at risk and living with lung cancer to confront the disease.

KnowYourBiomarker.org provides medically accurate patient educational materials in plain language, as well as patient stories and advocacy resources.

CONFRONTING LUNG CANCER STARTS HERE.

As your friends, your guides, your teachers, your advocates and your support system, GO2 is your go-to.

Learn more at go2.org.

Helpline: 1-800-298-2436
Traditionally, herpes zoster has been linked to adults over 50 years of age.

This presentation discusses key aspects of herpes zoster in patients at increased risk.

DANIEL VERDI, MD
Senior Director, Medical Lead Vaccines Clinical & US Medical Affairs
Association of Community Cancer Centers (ACCC)

Catch the Latest Content from ACCC!

Tune in to ACCC’s podcast channel to hear fresh takes on the hottest topics in oncology care delivery and their real-world impact.
ACCC-CANCER.ORG/Podcast

Subscribe to the ACCCBuzz blog for the latest news and views on a wide variety of timely education and advocacy developments.
ACCC-CANCER.ORG/ACCCBUZZ

Watch ACCC’s new, open-access video podcast channel for a deep dive in the latest developments in oncology care.
ACCC-CANCER.ORG/TV

Engage with your peers in ACCC’s members-only discussion forum which offers multidisciplinary perspectives on emergent issues.
ACCC.FORCE.COM/LOGIN

Driven by the needs of its diverse membership, ACCC’s peer-reviewed Journal provides “how-to” articles for the entire multidisciplinary cancer care team on a wide range of topics.
ACCC-CANCER.ORG/JOURNAL

Engage with ACCC on social media for the latest educational resources, important advocacy updates, ACCC member spotlights, and more. Like, follow, share & retweet!
ACCC-CANCER.ORG/SOCIAL

SAY YES to HOPE.org

Providing information, resources, support and HOPE for anyone affected by advanced cancer

877-937-7478

HOPE
Join us for our educational conference on cancer-related topics including:

- Understanding Health Insurance Options
- Managing Medical Bills
- Work and Cancer
- Disability Insurance
- Financial Help
- Estate Planning

...and more!

Register: TriageCancer.org/Conferences

Open to everyone. Free registration, gift bags, and prizes!

Free Online Conference
May 20, 2023

Legal & Financial Navigation Program
Free, one-on-one help for the cancer community.

- Health & Disability Insurance
- Employment
- Finances
- Medical Decision-Making
- Estate Planning
- And More!

Contact us: TriageCancer.org/GetHelp

Available in English and Spanish

Scan the QR code or visit www.livelung.org to learn more about LiveLung.

LiveLung is a proud member of the Lung Cancer Action Network, a collaborative association of advocacy organizations focused on serving the lung cancer community.

Since 2010, LiveLung has been on a mission to advance lung cancer education, early detection, and compassion for people impacted by lung cancer. We do this through our network of educational lung cancer patient groups and the educational resource bags we provide to dozens of cancer centers where nurse navigators distribute them to newly diagnosed lung cancer patients. LiveLung is a 501(c)(3) organization working for lung cancer awareness, education, and support for the lung cancer patient.

LiveLung is a Network of Educational Lung Cancer Patient Groups

LiveLung is a Network of Educational Lung Cancer Patient Groups

LiveLung is a Network of Educational Lung Cancer Patient Groups
Does molecular profiling help drive your treatment selection in newly diagnosed AML? **It should.** Mutated IDH1 (mIDH1) is an oncogenic driver in up to 10% of AML cases. More importantly, mIDH1 is an actionable target for treatment. That's why both the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the ASH-CAP Guidelines recommend performing molecular and cytogenetic analyses to identify IDH1 mutations in patients with AML. Further, the NCCN Guidelines® recommend expediting these analyses.

So the next time you have a patient with newly diagnosed, IC-ineligible AML, test for IDH1 mutation status **BEFORE** choosing treatment—your first step to treatment selection could be your patient's first step to better outcomes.

**References:**
2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed October 18, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

**ASH, American Society of Hematology; CAP, College of American Pathologists; IC, induction chemotherapy; IDH1, isocitrate dehydrogenase-1; NCCN, National Comprehensive Cancer Network.**

Learn more at AMLTreatmentOption.com
We’re in urology.

We’re listening. We’re learning.

We’re investing in urology-specific resources.

We’re advancing clinical innovations, so you can help patients.

We’re reimagining care so your patients with cancer can redefine living.

This is why we’re all in. For you—and for them.

We’re Janssen, and we’re in urology.
NCCN Guidelines for Patients®

Access 60+ FREE cancer resources

Acute Lymphoblastic Leukemia (adult)
Acute Lymphoblastic Leukemia (pediatric)
Acute Myeloid Leukemia
Adolescents and Young Adults with Cancer
Adrenal Tumors
Anal Cancer
Anemia and Neutropenia - Low Red and White Blood Cell Counts
Basal Cell Skin Cancer
B-Cell Lymphomas - Diffuse Large B-Cell Lymphoma
B-Cell Lymphomas - Follicular Lymphoma
B-Cell Lymphomas - Mantle Cell Lymphoma
B-Cell Lymphomas - Marginal Zone Lymphoma
Bladder Cancer
Bone Cancer
Brain Cancer - Gliomas
Breast Cancer - DCIS Breast Cancer
Breast Cancer - Invasive Breast Cancer
Breast Cancer - Metastatic Breast Cancer
Breast Cancer Screening and Diagnosis
Central Nervous System Cancers - Primary Central Nervous System Lymphoma
Cervical Cancer
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Colon Cancer
Colorectal Cancer Screening
Distress Management - Distress During Cancer Care
Esophageal Cancer
Gallbladder and Bile Duct Cancers
Graft-Versus-Host Disease
Head and Neck Cancers - Nasopharyngeal Cancer
Head and Neck Cancers - Oral Cancers
Head and Neck Cancers - Oropharyngeal Cancer
Hodgkin Lymphoma
Immunotherapy Side Effects: CAR T-Cell Therapy
Immunotherapy Side Effects: Immune Checkpoint Inhibitors
Kidney Cancer
Liver Cancer
Lung Cancer Screening
Malignant Pleural Mesothelioma
Melanoma
Multiple Myeloma
Mycosis Fungoides/Sézary Syndrome
Myelodysplastic Syndromes
Myeloproliferative Neoplasms
Nausea and Vomiting
Neuroendocrine Tumors
Non-Small Cell Lung Cancer - Early and Locally Advanced
Non-Small Cell Lung Cancer - Metastatic
Ovarian Cancer
Pancreatic Cancer
Peripheral T-Cell Lymphoma
Primary Cutaneous Lymphomas
Prostate Cancer: Advanced Stage
Prostate Cancer: Early Stage
Rectal Cancer
Small Cell Lung Cancer
Soft Tissue Sarcoma
Squamous Cell Skin Cancer
Stomach Cancer
Survivorship Care for Cancer-Related Late and Long-Term Effects
Survivorship Care for Healthy Living
Systemic Mastocytosis
Thyroid Cancer
Uterine Cancer
Waldenström Macroglobulinemia

Free access
NCCN.org/patientguidelines

Download the app:
NCCN.org/apps

Free copies as supplies are available:
NCCN.org/free-copies

while supplies last
Save These Dates

Hematologic Malignancies™

2023 Annual Congress:

Friday, September 22, 2023 – Saturday, September 23, 2023
Hilton San Francisco Union Square • San Francisco, CA

NCCN.org/hem
Virtual attendance available

See you next year!

Annual Conference 2024

April 5 - 7
Orlando World Center Marriott • Orlando, FL

NCCN.org/conference
Virtual attendance available